RecentMedicalFindings.com
Summarizing relevant biomedical research!
luteinizing hormone     Bookmark and Share
Search webpages of this site (RecentMedicalFindings):
Didn't find what you wanted? Try it at BioMedLib™ !
Search directly on the biomedical articles using BioMedLib™ search engine:



1. Biomedical articles (top 50; 2009 to 2014)
1. |||||||||. 100%  Troppmann B, Kleinau G, Krause G, Gromoll J: Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum Reprod Update; 2013 Sep-Oct;19(5):583-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor.
  • BACKGROUND In recent years it became evident that several types of the luteinizing hormone/choriogonadotrophin receptor (LHCGR) exist.
  • This specific exon 6A introduces a hitherto unknown regulatory pathway of the LHCGR at the transcriptional level which can lead to the expression of an alternative protein covering the extracellular part only.
  • Furthermore, an LHCGR type lacking exon 10 at the mRNA and protein levels has been described in the New World primate lineage, giving rise to an additional receptor type in which amino acids of the extracellular hinge region connecting the leucine-rich repeat domain and transmembrane domain are missing.
  • Structural homology models were retrieved from a glycoprotein hormone receptors web application and from recent publications.
  • CONCLUSIONS The complex system of different LHCGR types and two corresponding hormones (LH and CG) represents a major challenge for future studies on selective hormone binding, signal transduction and receptor regulation.
  • The presence of these naturally occurring LHCGR types requires re-examining of our present view on receptor function, experimental set-ups and data interpretation, but also offers new clinical approaches to interfere with LH/CG action in humans.
  • [MeSH-major] Evolution, Molecular. Receptors, LH / chemistry. Receptors, LH / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Chorionic Gonadotropin / metabolism. Exons. Humans. Luteinizing Hormone / metabolism. Mice. Models, Molecular. Molecular Sequence Data. Mutation. Primates / genetics. Protein Conformation. RNA, Messenger / genetics. Signal Transduction

  • HSDB. structure - CHORIONIC GONADOTROPIN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23686864.001).
  • [ISSN] 1460-2369
  • [Journal-full-title] Human reproduction update
  • [ISO-abbreviation] Hum. Reprod. Update
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / RNA, Messenger; 0 / Receptors, LH; 9002-67-9 / Luteinizing Hormone
  • [Keywords] NOTNLM ; choriogonadotrophin / evolution / genomic organization / gonadotrophins / luteinizing hormone receptor
  •  go-up   go-down


2. |||||||||. 92%  Kumar P, Sait SF: Luteinizing hormone and its dilemma in ovulation induction. J Hum Reprod Sci; 2011 Jan;4(1):2-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone and its dilemma in ovulation induction.
  • Concept of a 'therapeutic window' of luteinizing hormone (LH) for successful conception in assisted reproductive technology and ovulation induction has been reviewed in this literature.
  • The separate but complementary roles of follicle stimulating hormone and LH in stimulating folliculogenesis and ovulation are well established.
  • Levels under which low LH concentrations may be equally or suboptimally needed for oocyte quality and subsequent embryonic development competence has been reviewed along with the data related to the high levels of LH promoting follicular atresia.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Assist Reprod Genet. 2001 May;18(5):250-6 [11464575.001]
  • [Cites] Lancet. 1990 Nov 10;336(8724):1141-4 [1978024.001]
  • [Cites] Fertil Steril. 2001 Sep;76(3):543-9 [11532479.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):524-9 [11836280.001]
  • [Cites] Hum Reprod Update. 2002 Nov-Dec;8(6):543-57 [12498424.001]
  • [Cites] Hum Reprod. 2006 Jan;21(1):90-4 [16172149.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1309-16 [16434454.001]
  • [Cites] Lancet. 1986 Aug 30;2(8505):521-2 [2875271.001]
  • [Cites] Fertil Steril. 1987 Jan;47(1):22-34 [3539643.001]
  • [Cites] Br J Obstet Gynaecol. 1985 Apr;92(4):385-93 [3921051.001]
  • [Cites] Clin Obstet Gynecol. 1984 Dec;27(4):927-40 [6098403.001]
  • [Cites] Fertil Steril. 1993 Jun;59(6):1153-61 [8495757.001]
  • [Cites] BMJ. 1988 Oct 22;297(6655):1024-6 [3142595.001]
  • [Cites] Mol Cell Endocrinol. 2000 Mar 30;161(1-2):25-30 [10773387.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):337-43 [11232021.001]
  • [Cites] Hum Reprod. 2002 Aug;17(8):2016-21 [12151430.001]
  • [Cites] Semin Reprod Med. 2002 Nov;20(4):317-26 [12536355.001]
  • [Cites] Hum Reprod. 1991 Oct;6(9):1206-12 [1752920.001]
  • [Cites] Hum Reprod. 2001 Aug;16(8):1636-43 [11473955.001]
  • (PMID = 21772731.001).
  • [ISSN] 1998-4766
  • [Journal-full-title] Journal of human reproductive sciences
  • [ISO-abbreviation] J Hum Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3136063
  • [Keywords] NOTNLM ; Effects on ovulation / LH ceiling / ovulation induction
  •  go-up   go-down


3. ||||||||.. 82%  Choi J, Smitz J: Luteinizing hormone and human chorionic gonadotropin: origins of difference. Mol Cell Endocrinol; 2014 Mar 5;383(1-2):203-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone and human chorionic gonadotropin: origins of difference.
  • Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are widely recognized for their roles in ovulation and the support of early pregnancy.
  • Aside from the timing of expression, however, the differences between LH and hCG have largely been overlooked in the clinical realm because of their similar molecular structures and shared receptor.
  • With technologic advancements, including the development of highly purified and recombinant gonadotropins, researchers now appreciate that these hormones are not as interchangeable as once believed.
  • Although they bind to a common receptor, emerging evidence suggests that LH and hCG have disparate effects on downstream signaling cascades.
  • Increased understanding of the inherent differences between LH and hCG will foster more effective diagnostic and prognostic assays for use in a variety of clinical contexts and support the individualization of treatment strategies for conditions such as infertility.
  • [MeSH-major] Chorionic Gonadotropin / metabolism. Luteinizing Hormone / metabolism. Protein Subunits / metabolism. Receptors, LH / metabolism

  • Genetics Home Reference. consumer health - LHCGR Gene.
  • HSDB. structure - CHORIONIC GONADOTROPIN.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.
  • (PMID = 24365330.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Protein Subunits; 0 / Receptors, LH; 9002-67-9 / Luteinizing Hormone
  • [Keywords] NOTNLM ; Gonadotropin / Human chorionic gonadotropin / Luteinizing hormone / Luteinizing hormone receptor / Luteinizing hormone/choriogonadotropin receptor / Lutropin
  •  go-up   go-down


Advertisement
4. ||||||||.. 81%  Choi J, Smitz J: Luteinizing hormone and human chorionic gonadotropin: distinguishing unique physiologic roles. Gynecol Endocrinol; 2014 Mar;30(3):174-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone and human chorionic gonadotropin: distinguishing unique physiologic roles.
  • Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are integral components of the hypothalamic-pituitary-gonadal axis, which controls sexual maturation and functionality.
  • Whereas LH is a key regulator of gonadal steroidogenesis and ovulation, hCG is predominantly active in pregnancy and fetal development.
  • Spontaneous and induced mutations in LH, hCG and their mutual receptor have contributed substantially to our understanding of reproductive development and function.
  • Rescue of reproductive abnormalities resulting from aberrant gonadotropin signaling is possible in certain clinical contexts, depending on the nature of the underlying defect.
  • By understanding the physiologic roles of LH and hCG in normal and pathologic states, we may better harness their diagnostic, prognostic and therapeutic potential.
  • [MeSH-major] Chorionic Gonadotropin / physiology. Fetal Development. Luteinizing Hormone / physiology. Receptors, LH / physiology. Reproduction. Sexual Maturation. Signal Transduction

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • HSDB. structure - CHORIONIC GONADOTROPIN.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Mol Biol Transl Sci. 2009;89:97-114 [20374734.001]
  • [Cites] Endocrinology. 1993 May;132(5):2262-70 [8477671.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):863-72 [7690366.001]
  • [Cites] J Clin Invest. 1974 Mar;53(3):819-28 [4812441.001]
  • [Cites] Breast Cancer Res. 2007;9(4):R51 [17692113.001]
  • [Cites] Fertil Steril. 2008 Jun;89(6):1781-6 [17675003.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Dec;93(12):4697-706 [18782867.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):3-4 [19126631.001]
  • [Cites] Horm Res. 2009;71(2):75-82 [19129711.001]
  • [Cites] Reprod Biol Endocrinol. 2010;8:102 [20735820.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2011 Apr;25(2):303-19 [21397200.001]
  • [Cites] J Clin Endocrinol Metab. 2011 Jul;96(7):E1197-205 [21490077.001]
  • [Cites] Fertil Steril. 2011 Aug;96(2):e125-30 [21683950.001]
  • [Cites] Vasc Health Risk Manag. 2011;7:467-74 [21822394.001]
  • [Cites] Rev Endocr Metab Disord. 2011 Dec;12(4):275-88 [21706143.001]
  • [Cites] Obstet Gynecol. 2012 Feb;119(2 Pt 1):263-9 [22270277.001]
  • [Cites] Mol Cell Endocrinol. 2012 Apr 4;351(2):279-85 [22245602.001]
  • [Cites] Biol Reprod. 2012 Mar;86(3):87 [21832169.001]
  • [Cites] Mol Biol Rep. 2012 Jun;39(6):7117-23 [22327646.001]
  • [Cites] Fertil Steril. 2012 May;97(5):1165-8 [22369774.001]
  • [Cites] Mol Hum Reprod. 2012 Aug;18(8):379-90 [22554618.001]
  • [Cites] Reprod Biol Endocrinol. 2012;10:36 [22546001.001]
  • [Cites] J Assist Reprod Genet. 2012 Jul;29(7):609-14 [22527905.001]
  • [Cites] J Clin Endocrinol Metab. 2012 Sep;97(9):E1741-4 [22745244.001]
  • [Cites] Gynecol Oncol. 2012 Nov;127(2):403-5 [22902918.001]
  • [Cites] Reprod Fertil Dev. 2013;25(3):511-22 [23464498.001]
  • [Cites] FASEB J. 2013 Apr;27(4):1309-21 [23233533.001]
  • [Cites] Reprod Sci. 2013 Sep;20(9):1038-45 [23439616.001]
  • [Cites] Mol Endocrinol. 2001 Jan;15(1):184-200 [11145749.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):80-9 [11231982.001]
  • [Cites] Hum Reprod. 2001 Jun;16(6):1058-64 [11387269.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2643-8 [11397866.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Jul;227(7):455-64 [12094009.001]
  • [Cites] Prenat Diagn. 2002 Jun;22(6):478-81 [12116306.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4084-95 [12239120.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):5290-6 [12414904.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2242-9 [12727981.001]
  • [Cites] Eur J Hum Genet. 2003 May;11(5):402-8 [12734546.001]
  • [Cites] Prostate. 2003 Jun 15;56(1):30-6 [12746844.001]
  • [Cites] Biol Reprod. 2003 Jul;69(1):338-46 [12672665.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4682-8 [14557441.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4980-90 [12960071.001]
  • [Cites] Clin Chem. 2003 Dec;49(12):2045-9 [14633876.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):952-6 [14764820.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Apr;40(4):545-51 [1127071.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Aug;45(2):307-11 [885995.001]
  • [Cites] Clin Endocrinol Metab. 1978 Nov;7(3):487-511 [215355.001]
  • [Cites] J Pediatr. 1980 Aug;97(2):205-13 [7400887.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Dec;47(6):1216-9 [318094.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Apr;64(4):730-6 [3546353.001]
  • [Cites] Pediatr Res. 1987 Apr;21(4):409-13 [2437520.001]
  • [Cites] N Engl J Med. 1987 Dec 31;317(27):1688-91 [3696177.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Sep;69(3):528-32 [2760168.001]
  • [Cites] N Engl J Med. 1992 Jan 16;326(3):179-83 [1727547.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Apr;74(4):890-7 [1548356.001]
  • [Cites] Clin Chem. 1992 Oct;38(10):1981-7 [1382894.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):885-9 [8473400.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):270-4 [10634398.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2281-6 [10852464.001]
  • [Cites] Mol Endocrinol. 2001 Jan;15(1):172-83 [11145748.001]
  • [Cites] Reprod Biol Endocrinol. 2009;7:8 [19171054.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Nov;94(11):4567-74 [19837939.001]
  • [Cites] N Engl J Med. 2009 Nov 5;361(19):1856-63 [19890128.001]
  • [Cites] Endocr Rev. 2009 Dec;30(7):883-925 [19887492.001]
  • [Cites] Horm Res Paediatr. 2010;73(2):93-101 [20190545.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1419-23 [7515388.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1257-63 [7714098.001]
  • [Cites] Fertil Steril. 1995 May;63(5):989-95 [7720944.001]
  • [Cites] Horm Res. 1995;43(1-3):25-8 [7721258.001]
  • [Cites] Genes Dev. 1995 Aug 15;9(16):2007-19 [7544315.001]
  • [Cites] Fertil Steril. 1997 Jun;67(6):998-1004 [9176435.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3103-6 [9284752.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):675-81 [9467591.001]
  • [Cites] Mol Hum Reprod. 1998 Jul;4(7):631-9 [9701785.001]
  • [Cites] Eur J Endocrinol. 1998 Dec;139(6):621-30 [9916868.001]
  • [Cites] Fertil Steril. 1999 Jan;71(1):96-101 [9935123.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1711-5 [10323405.001]
  • [Cites] J Reprod Fertil. 1999 Mar;115(2):293-301 [10434935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17294-9 [15569941.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2619-25 [15602022.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1830-5 [16099935.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1470-6 [16464948.001]
  • [Cites] Mol Cell Endocrinol. 2007 Apr 15;269(1-2):85-92 [17367920.001]
  • [Cites] N Engl J Med. 2007 Aug 30;357(9):897-904 [17761593.001]
  • [Cites] Prenat Diagn. 2007 Sep;27(9):808-13 [17590886.001]
  • [Cites] Gynecol Obstet Invest. 2007;64(3):156-60 [17934312.001]
  • (PMID = 24283620.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Receptors, LH; 9002-67-9 / Luteinizing Hormone
  • [Other-IDs] NLM/ PMC3956631
  •  go-up   go-down


5. ||||||||.. 81%  Kawaguchi S, Sakumoto R, Okuda K: Induction of the expressions of antioxidant enzymes by luteinizing hormone in the bovine corpus luteum. J Reprod Dev; 2013;59(3):219-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of the expressions of antioxidant enzymes by luteinizing hormone in the bovine corpus luteum.
  • Luteoprotective mechanisms of luteinizing hormone (LH) involved in the maintenance of bovine corpus luteum (CL) function have not been completely clarified.
  • Since antioxidant enzymes are well documented as antiapoptotic factors in the CL of many mammals, we hypothesized that the luteoprotective action of LH is mediated by stimulating the local production and action of antioxidant enzymes.
  • To test the above hypothesis, in the present study, we examined the mechanisms involved in the luteoprotective actions of LH.
  • Cultured bovine luteal cells obtained from the CL at the mid-luteal stage (days 8-12 of the estrous cycle) were treated with LH (10 ng/ml), onapristone (OP; a specific progesterone receptor antagonist, 100 μM) and diethyldithiocarbamate [DETC; an inhibitor of superoxide dismutase (SOD), 100 μM] for 24 h.
  • LH in combination with or without OP significantly increased the mRNA and protein expressions of manganese SOD (Mn-SOD) and catalase (CATA) and SOD activity.
  • While LH alone significantly increased the mRNA and protein expressions of SOD containing copper and zinc (Cu,Zn-SOD), OP in combination with or without LH significantly decreased the mRNA and protein expressions of Cu,Zn-SOD.
  • LH in combination with DETC significantly decreased LH-increased cell viability.
  • The overall results suggest that LH increases cell viability by LH-increased antioxidant enzymes, resulting in maintenance of CL function during the luteal phase in cattle.
  • [MeSH-major] Antioxidants / metabolism. Corpus Luteum / metabolism. Gene Expression Regulation, Enzymologic. Luteinizing Hormone / metabolism. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Animals. Apoptosis. Catalase / metabolism. Cattle. Cell Survival. Female. Luteal Phase. Progesterone / metabolism. RNA, Messenger / metabolism. Receptors, Progesterone / metabolism. Superoxide Dismutase / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • HSDB. structure - PROGESTERONE.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Physiol Rev. 2000 Jan;80(1):1-29 [10617764.001]
  • [Cites] Biol Reprod. 2000 Feb;62(2):398-403 [10642579.001]
  • [Cites] Mol Hum Reprod. 2000 Jan;6(1):19-25 [10611256.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Reprod Dev. 2010 Aug;56(4):454-9 [20519832.001]
  • [Cites] Biochem Biophys Res Commun. 2010 Mar 12;393(3):449-54 [20152804.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1717-26 [17218406.001]
  • [Cites] Domest Anim Endocrinol. 2006 Oct;31(3):246-57 [16332426.001]
  • [Cites] J Reprod Dev. 2006 Jun;52(3):353-61 [16493180.001]
  • [Cites] Biol Reprod. 2004 Dec;71(6):2065-71 [15329328.001]
  • [Cites] Biol Reprod. 1998 Jul;59(1):208-15 [9675014.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 12;1380(1):133-40 [9545562.001]
  • [Cites] Biol Reprod. 1997 Mar;56(3):625-31 [9047006.001]
  • [Cites] Biol Reprod. 1994 Dec;51(6):1248-54 [7888502.001]
  • [Cites] Scand J Clin Lab Invest. 1993 Nov;53(7):757-63 [8272764.001]
  • [Cites] Biol Reprod. 1992 Jun;46(6):1001-6 [1327197.001]
  • [Cites] J Anim Sci. 1986 Jul;63(1):162-8 [3460979.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):2-10 [14973264.001]
  • [Cites] J Reprod Dev. 2004 Apr;50(2):257-61 [15118253.001]
  • [Cites] Front Biosci. 2002 Sep 1;7:d1879-98 [12161340.001]
  • [Cites] Biol Reprod. 2000 May;62(5):1109-15 [10775155.001]
  • [Cites] Steroids. 2000 Oct-Nov;65(10-11):713-23 [11108882.001]
  • [Cites] J Biochem. 2001 Jun;129(6):937-42 [11388909.001]
  • [Cites] Mol Hum Reprod. 2002 Jan;8(1):68-74 [11756571.001]
  • [Cites] Hum Reprod. 2002 Jul;17(7):1709-14 [12093828.001]
  • (PMID = 23386101.001).
  • [ISSN] 1348-4400
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; 9002-67-9 / Luteinizing Hormone; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC3934140
  •  go-up   go-down


6. ||||||||.. 81%  Stephens SM, Pau FK, Yalcinkaya TM, May MC, Berga SL, Post MD, Appt SE, Polotsky AJ: Assessing the pulsatility of luteinizing hormone in female vervet monkeys (Chlorocebus aethiops sabaeus). Comp Med; 2013 Oct;63(5):432-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the pulsatility of luteinizing hormone in female vervet monkeys (Chlorocebus aethiops sabaeus).
  • Specific alterations in the pulsatility of luteinizing hormone (LH) are linked to obesity-related subfertility in ovulatory women.
  • We evaluated follicular-phase LH pulses in 12 adult normal-weight female vervets.
  • Serum was collected every 10 min for 4 h by using a tether device in conscious, freely moving monkeys on menstrual cycle days 2 through 5.
  • Serum estradiol was collected daily during the follicular phase to identify the luteal-follicular transition.
  • For comparison, we used data from 12 ovulatory normal-weight women who had undergone frequent blood sampling of early-follicular LH.
  • LH pulse frequency was similar, with 2.8 ± 0.7 LH pulses during 4 h in vervets compared with 2.3 ± 0.7 LH pulses during 4 h in women.
  • The LH pulse mass (percentage change in the pulse peak over the preceding nadir) was 123.2% ± 27.4% in vervets and 60.9% ± 14.9% in humans.
  • The first day of low serum estradiol after the follicular-phase peak was denoted as the day of the luteal-follicular transition.
  • We demonstrate that follicular LH patterns in vervets are similar to those in humans and that the luteal phase is easily identified by monitoring daily serum estradiol.
  • These findings demonstrate that vervet monkeys are a suitable animal model for evaluating LH pulse dynamics longitudinally in studies of diet-induced obesity.
  • [MeSH-major] Cercopithecus aethiops / blood. Luteinizing Hormone / blood. Menstrual Cycle / blood

  • HSDB. structure - ESTRADIOL.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ILAR J. 2003;44(3):222-35 [12789023.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Jun;62(6):1136-44 [3084534.001]
  • [Cites] Fertil Steril. 1988 Oct;50(4):567-72 [2971578.001]
  • [Cites] Gynecol Endocrinol. 1990 Mar;4(1):1-13 [2110712.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1140-6 [8496304.001]
  • [Cites] Cell Mol Neurobiol. 1995 Feb;15(1):141-64 [7648606.001]
  • [Cites] Fertil Steril. 1997 Jun;67(6):1024-30 [9176439.001]
  • [Cites] Hum Reprod. 1997 Oct;12 Suppl 1:26-32 [9403319.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):342-9 [9920105.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1028-36 [10084591.001]
  • [Cites] Am J Primatol. 2007 Aug;69(8):901-16 [17294431.001]
  • [Cites] Am J Primatol. 2007 Aug;69(8):890-900 [17294432.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jul;92(7):2468-73 [17440019.001]
  • [Cites] Obesity (Silver Spring). 2007 Jul;15(7):1666-74 [17636084.001]
  • [Cites] Fertil Steril. 2009 Oct;92(4):1410-5 [18829008.001]
  • [Cites] Am J Obstet Gynecol. 2010 Dec;203(6):525-30 [20739012.001]
  • [Cites] Comp Med. 2011 Dec;61(6):514-26 [22330579.001]
  • [Cites] Front Neuroendocrinol. 2012 Apr;33(2):160-8 [22410547.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):258-67 [22923428.001]
  • [Cites] Syst Biol Reprod Med. 2013 Apr;59(2):74-81 [23278149.001]
  • [Cites] Fertil Steril. 2004 Jan;81(1):114-9 [14711553.001]
  • [Cites] J Clin Endocrinol Metab. 1973 Aug;37(2):326-8 [4198259.001]
  • [Cites] J Clin Invest. 1973 Oct;52(10):2617-28 [4729055.001]
  • [Cites] Acta Endocrinol (Copenh). 1973 Aug;73(4):751-8 [4200885.001]
  • [Cites] Endocrinology. 1975 Jan;96(1):219-26 [1167352.001]
  • [Cites] Proc Soc Exp Biol Med. 1977 Sep;155(4):479-81 [408814.001]
  • [Cites] Endocrinology. 1981 Dec;109(6):2270-2 [6796391.001]
  • [Cites] Endocrinology. 1984 Jul;115(1):261-6 [6539670.001]
  • [Cites] J Endocrinol. 1986 Sep;110(3):429-39 [3760741.001]
  • (PMID = 24210020.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 2 P51 RR00163; United States / NIMH NIH HHS / MH / R01MH50748; United States / NICHD NIH HHS / HD / R21 1R21HD060944; United States / NCRR NIH HHS / RR / RR00056; United States / NCRR NIH HHS / RR / RR019963; United States / NICHD NIH HHS / HD / U54 HD058155; United States / NICHD NIH HHS / HD / U54 HD08610
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone
  • [Other-IDs] NLM/ PMC3796754
  •  go-up   go-down


7. ||||||||.. 81%  Kawaguchi S, Bowolaksono A, Yoshioka S, Sakumoto R, Okuda K: Luteoprotective mechanisms of prostaglandin F2α stimulated by luteinizing hormone in the bovine corpus luteum. J Reprod Dev; 2013;59(3):225-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteoprotective mechanisms of prostaglandin F2α stimulated by luteinizing hormone in the bovine corpus luteum.
  • Luteinizing hormone (LH) regulates several ovarian functions.
  • However, the luteoprotective mechanisms of LH involved in the maintenance of bovine corpus luteum (CL) function are not well understood.
  • Since prostaglandin F2α (PGF), PGE2 and progesterone (P4) are well documented as antiapoptotic factors in the bovine CL, we hypothesized that LH protects the CL by stimulating the local production and action of PGF, PGE2 and P4.
  • Cultured bovine luteal cells obtained at the mid-luteal stage (days 8-12 of the estrous cycle) were treated with LH (10 ng/ml), onapristone (OP: a specific P4 receptor antagonist, 100 μM) and indomethacin [INDO; a cyclooxygenase (COX) inhibitor, 100 μM] for 24 h.
  • LH with and without OP significantly increased the mRNA and protein expressions of COX-2, PGF synthase and carbonyl reductase (P<0.05) but not the mRNA and protein expressions of COX-1 and PGE synthase in bovine luteal cells.
  • Luteal cell viability was significantly increased by LH alone (P<0.05), but LH-increased cell viability was reduced by LH in combination with INDO as well as OP (P<0.05).
  • The overall results suggest that LH prevents luteal cell death by stimulating luteal PGF and P4 production and supports CL function during the luteal phase in cattle.
  • [MeSH-major] Corpus Luteum / metabolism. Dinoprost / metabolism. Luteinizing Hormone / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cattle. Cell Survival / drug effects. DNA, Complementary / metabolism. Dinoprostone / metabolism. Estrus / drug effects. Female. Gonanes / chemistry. Hormones / metabolism. Indomethacin / chemistry. Luteal Cells / metabolism. Ovary / metabolism. Progesterone / metabolism. Real-Time Polymerase Chain Reaction. Time Factors

  • HSDB. structure - INDOMETHACIN.
  • HSDB. structure - PROSTAGLANDIN F2ALPHA.
  • HSDB. structure - PROGESTERONE.
  • ExactAntigen/Labome. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2004 May;145(5):2551-60 [14736737.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2003 Jan;70(3-4):339-49 [12611498.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Nov 10;1:95 [14613529.001]
  • [Cites] Adv Cyclic Nucleotide Res. 1978;9:573-82 [208397.001]
  • [Cites] Br J Pharmacol. 2010 Jan 1;159(2):265-84 [19912228.001]
  • [Cites] Endocrinology. 2010 Apr;151(4):1914-22 [20176726.001]
  • [Cites] Biol Reprod. 1983 Dec;29(5):1063-8 [6418223.001]
  • [Cites] Biol Reprod. 2008 Aug;79(2):310-7 [18463360.001]
  • [Cites] Stem Cells Dev. 2008 Feb;17(1):81-91 [18208372.001]
  • [Cites] J Endocrinol. 2007 Sep;194(3):499-510 [17761889.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):117-49 [17077191.001]
  • [Cites] Domest Anim Endocrinol. 2006 Oct;31(3):246-57 [16332426.001]
  • [Cites] J Reprod Dev. 2006 Aug;52(4):517-22 [16679718.001]
  • [Cites] Biol Reprod. 2004 Dec;71(6):2065-71 [15329328.001]
  • [Cites] Physiol Rev. 1999 Apr;79(2):263-323 [10221982.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1675-87 [9501089.001]
  • [Cites] Rev Reprod. 1996 Sep;1(3):162-72 [9414454.001]
  • [Cites] Biol Reprod. 1997 Mar;56(3):625-31 [9047006.001]
  • [Cites] Adv Immunol. 1996;62:167-215 [8781269.001]
  • [Cites] Mol Cell Endocrinol. 1994 Apr;100(1-2):87-91 [8056164.001]
  • [Cites] Scand J Clin Lab Invest. 1993 Nov;53(7):757-63 [8272764.001]
  • [Cites] Endocrinology. 1993 Jan;132(1):249-54 [8419126.001]
  • [Cites] Biol Reprod. 1992 Jun;46(6):1001-6 [1327197.001]
  • [Cites] Prostaglandins. 1989 Sep;38(3):307-18 [2781046.001]
  • [Cites] Domest Anim Endocrinol. 1988 Apr;5(2):91-107 [3066583.001]
  • [Cites] Biochem J. 1986 Aug 1;237(3):797-805 [3026333.001]
  • [Cites] J Reprod Fertil. 1985 Nov;75(2):491-9 [4067928.001]
  • [Cites] J Reprod Fertil. 1984 Jul;71(2):493-501 [6540310.001]
  • [Cites] Biochem Biophys Res Commun. 2012 Jun 22;423(1):85-90 [22634003.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Biol Reprod. 2000 May;62(5):1109-15 [10775155.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):845-53 [11376105.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2002 Jan;67(1):49-60 [11789897.001]
  • [Cites] Reproduction. 2002 Mar;123(3):333-9 [11882010.001]
  • [Cites] Trends Cell Biol. 2002 Jun;12(6):258-66 [12074885.001]
  • [Cites] J Reprod Dev. 2004 Apr;50(2):257-61 [15118253.001]
  • (PMID = 23358309.001).
  • [ISSN] 1348-4400
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Gonanes; 0 / Hormones; 4G7DS2Q64Y / Progesterone; 9002-67-9 / Luteinizing Hormone; 96346-61-1 / onapristone; B7IN85G1HY / Dinoprost; K7Q1JQR04M / Dinoprostone; XXE1CET956 / Indomethacin
  • [Other-IDs] NLM/ PMC3934132
  •  go-up   go-down


8. |||||||||. 123%  Goebel C: Stimulating luteinizing hormone. Drug Test Anal; 2011 Nov-Dec;3(11-12):868-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulating luteinizing hormone.
  • Low molecular weight luteinizing hormone (LMWLH) receptor agonists could be of interest as a potential doping substance for athletes.
  • These orally active compounds induce the production of endogenous hormones such as testosterone in a similar way to LH.
  • A method for the detection of these compounds needs to be direct as their effect--the excess production of endogenous hormones--cannot be proven by analysis techniques which test for endogenous hormones.
  • [MeSH-major] Pyrazoles / urine. Pyrimidines / urine. Receptors, LH / agonists. Substance Abuse Detection / methods. Thiophenes / urine
  • [MeSH-minor] Chromatography, Liquid / methods. Doping in Sports. Humans. Luteinizing Hormone / metabolism. Sensitivity and Specificity. Tandem Mass Spectrometry / methods

  • HSDB. structure - THIOPHENE.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 John Wiley & Sons, Ltd.
  • (PMID = 22147514.001).
  • [ISSN] 1942-7611
  • [Journal-full-title] Drug testing and analysis
  • [ISO-abbreviation] Drug Test Anal
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-amino-2-methylsulfanyl-4-(3-(2-morpholin-4-ylacetylamino)phenyl)thieno(2,3-d)pyrimidine-6-carboxylic acid tert-butylamide; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Receptors, LH; 0 / Thiophenes; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


9. |||||||||. 107%  Mezo G, Manea M: Luteinizing hormone-releasing hormone antagonists. Expert Opin Ther Pat; 2009 Dec;19(12):1771-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone antagonists.
  • BACKGROUND: Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity.
  • Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.
  • OBJECTIVE/METHOD: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications.
  • CONCLUSION: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors.
  • Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.
  • [MeSH-major] Fertilization in Vitro / methods. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19939192.001).
  • [ISSN] 1744-7674
  • [Journal-full-title] Expert opinion on therapeutic patents
  • [ISO-abbreviation] Expert Opin Ther Pat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 100
  •  go-up   go-down


10. |||||||||. 92%  van Gastel P, van der Zanden M, Telting D, Filius M, Bancsi L, de Boer H: Luteinizing hormone-releasing hormone receptor antagonist may reduce postmenopausal flushing. Menopause; 2012 Feb;19(2):178-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone receptor antagonist may reduce postmenopausal flushing.
  • OBJECTIVE: Hormone therapy (HT) is the most effective treatment of postmenopausal (PMP) flushing; however, its use is often contraindicated.
  • As an alternative option, we explored the efficacy of the luteinizing hormone-releasing hormone (LHRH) receptor antagonist cetrorelix in women with severe PMP flushing.
  • The response to treatment was evaluated through monitoring serum gonadotropin levels, flush scores, and quality of life.
  • All women demonstrated a decrease in serum luteinizing hormone and follicle-stimulating hormone during treatment, but the premenopausal levels of both gonadotropins were reached in only two women.
  • CONCLUSIONS: In an open-label setting, luteinizing hormone-releasing hormone receptor blockade reduced PMP flushing by at least 25% in 8 of 10 women with severe flushing.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Hot Flashes / drug therapy. Postmenopause. Receptors, LHRH / antagonists & inhibitors
  • [MeSH-minor] Aged. Female. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Middle Aged. Pilot Projects. Quality of Life

  • HSDB. structure - CETRORELIX.
  • HSDB. structure - MENOTROPINS.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21926922.001).
  • [ISSN] 1530-0374
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; OON1HFZ4BA / cetrorelix
  •  go-up   go-down


11. ||||||||.. 81%  Schumacher A, Poloski E, Spörke D, Zenclussen AC: Luteinizing hormone contributes to fetal tolerance by regulating adaptive immune responses. Am J Reprod Immunol; 2014 May;71(5):434-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone contributes to fetal tolerance by regulating adaptive immune responses.
  • Recently, we showed that human chorionic gonadotropin (hCG) not only increases the number and activity of regulatory T cells (Treg) but also retains tolerogenic dendritic cells (DCs).
  • Here, we investigate whether the highly homologous luteinizing hormone (LH) modulates Treg number and DC phenotype and thereby supports pregnancy.
  • METHOD OF STUDY: Abortion-prone females were treated with LH or PBS on different gestation days.
  • RESULTS: We discovered that LH application completely prevented fetal rejection in abortion-prone females.
  • Moreover, LH reduced the number of total and mature DCs.
  • CONCLUSION: Our data suggest that LH, similar to hCG, is involved in the regulation of adaptive immune responses, thus contributing to fetal tolerance.

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 24592927.001).
  • [ISSN] 1600-0897
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Keywords] NOTNLM ; Dendritic cell / Treg / luteinizing hormone / pregnancy
  •  go-up   go-down


12. ||||||||.. 81%  Suzuki H, Yamamoto T: Leucine-enkephalin-like immunoreactivity is localized in luteinizing hormone-producing cells in the axolotl (Ambystoma mexicanum) pituitary. Tissue Cell; 2014 Feb;46(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leucine-enkephalin-like immunoreactivity is localized in luteinizing hormone-producing cells in the axolotl (Ambystoma mexicanum) pituitary.
  • In this study, we used immunohistochemical techniques to determine the cell type of leucine-enkephalin (Leu-ENK)-immunoreactive cells in the axolotl (Ambystoma mexicanum) pituitary.
  • These cells were immuno-positive for luteinizing hormone (LH), but they were immuno-negative for adrenocorticotrophic, growth, and thyroid-stimulating hormones, as well as prolactin.
  • Immunoelectron microscopy demonstrated that Leu-ENK-like substance and LH co-localized within the same secretory granules.
  • Leu-ENK secreted from gonadotrophs may participate in LH secretion in an autocrine fashion, and/or may participate in the release of sex steroids together with LH.
  • [MeSH-major] Ambystoma mexicanum / metabolism. Enkephalin, Leucine / metabolism. Follicle Stimulating Hormone / metabolism. Luteinizing Hormone / biosynthesis. Pituitary Gland / metabolism

  • HSDB. structure - MENOTROPINS.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Elsevier Ltd. All rights reserved.
  • (PMID = 24034715.001).
  • [ISSN] 1532-3072
  • [Journal-full-title] Tissue & cell
  • [ISO-abbreviation] Tissue Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 58822-25-6 / Enkephalin, Leucine; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin
  • [Keywords] NOTNLM ; Amphibian / Axolotl / Enkephalin / Luteinizing hormone / Pituitary
  •  go-up   go-down


13. ||||||||.. 81%  Li DY, Zhang L, Yang MY, Xu HL, Yin HD, Li Y, Zhu Q: Effect of luteinizing hormone/choriogonadotropin receptor (LHCGR) gene on chicken reproductive traits. Mol Biol Rep; 2013 Dec;40(12):7111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of luteinizing hormone/choriogonadotropin receptor (LHCGR) gene on chicken reproductive traits.
  • Luteinizing hormone/choriogonadotropin receptor (LHCGR) gene, potentially related to reproductive traits in chickens, was genotyped by using the Pooled DNA Sequencing, PCR-SSCP and Directing Sequencing techniques.
  • The associations between LHCGR polymorphisms and six reproductive traits [body weight at first egg (BWAFE), weight of first egg, age at first egg (AFE), number of eggs at 300 days of age (EN), body weight at 300 days of age and egg weight at 300 days of age (EWTA)] were estimated using the one-way analysis of variance method.
  • Birds with the AG genotype for the +G4058A SNP exhibited shorter AFE (P < 0.05) and greater EN than those of the GG and AA genotypes, suggesting a balancing selection (overdominance); the effect of allele C in SNP +C3021T and allele C in SNP +T4490C on EN and AFE is additive and may reflect the influence of positive selection.
  • [MeSH-major] Chickens / genetics. Quantitative Trait, Heritable. Receptors, LH / genetics. Reproduction / genetics

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24190488.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Receptors, LH
  •  go-up   go-down


14. ||||||||.. 81%  Rick FG, Block NL, Schally AV: Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin Pharmacother; 2013 Nov;14(16):2237-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agonists of luteinizing hormone-releasing hormone in prostate cancer.
  • INTRODUCTION: Androgen deprivation therapy (ADT) has been the first-line standard of care for treating patients with hormone-sensitive advanced prostate cancer (PCa) for many decades.
  • The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23984804.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


15. ||||||||.. 81%  Vaccari S, Weeks JL 2nd, Hsieh M, Menniti FS, Conti M: Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes. Biol Reprod; 2009 Sep;81(3):595-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes.
  • It is well established that cAMP signaling is an important regulator of the oocyte meiotic cell cycle.
  • Herein, we evaluated the expression of cGMP-hydrolyzing phosphodiesterases (PDEs) in the somatic and germ cell compartments of the mouse ovarian follicle and demonstrate that PDE5 is preferentially expressed in somatic cells.
  • Luteinizing hormone (LH) stimulation of cultured preovulatory follicles results in a marked decrease in cGMP content, and a nadir is reached in 1.5 h; similarly, oocyte cGMP levels decrease after gonadotropin stimulation in vivo.
  • The LH-dependent decrease in cGMP requires activation of the epidermal growth factor network.
  • Treatment of follicles with a PDE5 inhibitor increases cGMP in the follicle well above unstimulated levels.
  • Although LH causes a decrease in cGMP in follicles preincubated with PDE5 inhibitors, the levels of this nucleotide remain above unstimulated levels.
  • Under these conditions of elevated cGMP, LH stimulation does not cause oocyte maturation after 5 h of incubation.
  • [MeSH-major] Cyclic GMP / physiology. Luteinizing Hormone / pharmacology. Meiosis / drug effects. Oocytes / drug effects

  • ResearchGate. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Theriogenology. 2007 Sep 15;68(5):693-701 [17604095.001]
  • [Cites] Endocrinology. 2006 May;147(5):2280-6 [16439460.001]
  • [Cites] Mol Endocrinol. 2008 Apr;22(4):924-36 [18187604.001]
  • [Cites] Dev Biol. 2008 Apr 1;316(1):124-34 [18280465.001]
  • [Cites] Biol Reprod. 2008 Jun;78(6):1111-8 [18337515.001]
  • [Cites] Front Biosci. 2008;13:7087-95 [18508718.001]
  • [Cites] Development. 2008 Oct;135(19):3229-38 [18776144.001]
  • [Cites] Endocrinology. 2008 Nov;149(11):5568-76 [18669600.001]
  • [Cites] J Exp Zool. 1977 Jul;201(1):139-47 [196033.001]
  • [Cites] Acta Endocrinol (Copenh). 1978 Feb;87(2):377-8 [204141.001]
  • [Cites] Dev Biol. 1981 Sep;86(2):356-62 [6793428.001]
  • [Cites] EMBO J. 2006 Dec 13;25(24):5716-25 [17124499.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1914-24 [17194751.001]
  • [Cites] Biol Reprod. 1982 Mar;26(2):230-40 [6279189.001]
  • [Cites] Biol Reprod. 1982 May;26(4):628-32 [6282351.001]
  • [Cites] Cell Differ. 1983 May;12(5):271-6 [6189621.001]
  • [Cites] Dev Biol. 1983 Nov;100(1):39-49 [6194027.001]
  • [Cites] Endocrinology. 1984 Jun;114(6):2361-8 [6202500.001]
  • [Cites] J Endocrinol. 1984 Jun;101(3):305-10 [6144719.001]
  • [Cites] Acta Physiol Scand. 1984 Dec;122(4):507-13 [6098139.001]
  • [Cites] Dev Biol. 1986 Feb;113(2):517-21 [3949077.001]
  • [Cites] Biol Reprod. 1987 Mar;36(2):431-7 [2883997.001]
  • [Cites] J Exp Zool. 1988 Jan;245(1):86-96 [2832512.001]
  • [Cites] Dev Biol (N Y 1985). 1985;1:313-47 [3917204.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3380-6 [10828019.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;65:1-52 [11008484.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;66:241-77 [11051766.001]
  • [Cites] Biol Reprod. 2001 Nov;65(5):1444-51 [11673261.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):153-9 [11988323.001]
  • [Cites] Endocr J. 2002 Apr;49(2):219-26 [12081242.001]
  • [Cites] Biol Reprod. 2002 Nov;67(5):1588-92 [12390892.001]
  • [Cites] Mol Pharmacol. 2003 Jun;63(6):1364-72 [12761347.001]
  • [Cites] Dev Biol. 2003 Jun 15;258(2):385-96 [12798295.001]
  • [Cites] Science. 2004 Jan 30;303(5658):682-4 [14726596.001]
  • [Cites] J Clin Invest. 2004 Jul;114(2):196-205 [15254586.001]
  • [Cites] Mol Cell Endocrinol. 2004 Aug 31;223(1-2):85-93 [15279914.001]
  • [Cites] J Exp Zool. 1974 Mar;187(3):383-6 [4362350.001]
  • [Cites] Endocrinology. 1976 Dec;99(6):1496-500 [187411.001]
  • [Cites] Mol Pharmacol. 1990 May;37(5):671-81 [2160060.001]
  • [Cites] Acta Physiol Scand. 1990 Jul;139(3):511-7 [2173353.001]
  • [Cites] Hum Reprod. 1991 Mar;6(3):411-22 [1659586.001]
  • [Cites] Mol Pharmacol. 1993 Nov;44(5):1027-35 [8246905.001]
  • [Cites] Dev Biol. 1996 Sep 15;178(2):393-402 [8812137.001]
  • [Cites] J Urol. 1998 Jun;159(6):2164-71 [9598563.001]
  • [Cites] Hum Reprod. 1999 Oct;14(10):2537-43 [10527984.001]
  • [Cites] Science. 2004 Dec 10;306(5703):1947-50 [15591206.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1236-44 [15576461.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3060-6 [16123402.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):249-61 [16229830.001]
  • [Cites] Biochemistry. 2007 Sep 11;46(36):10353-64 [17696499.001]
  • (PMID = 19474061.001).
  • [ISSN] 1529-7268
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD052909; United States / NIGMS NIH HHS / GM / R01 GM080527; United States / NICHD NIH HHS / HD / R01 HD052909
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 9002-67-9 / Luteinizing Hormone; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 3; EC 3.1.4.17 / Pde3a protein, mouse; H2D2X058MU / Cyclic GMP
  • [Other-IDs] NLM/ PMC2731981
  •  go-up   go-down


16. ||||||||.. 80%  Saxena AR, Seely EW: Luteinizing hormone correlates with adrenal function in postmenopausal women. Menopause; 2012 Nov;19(11):1280-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone correlates with adrenal function in postmenopausal women.
  • OBJECTIVE: In postmenopausal women, a relationship between luteinizing hormone (LH) and cortisol levels has been suggested.
  • Furthermore, LH receptors in the adrenal gland have been shown to mediate adrenocorticotropic hormone-independent Cushing syndrome.
  • In contrast, follicle-stimulating hormone (FSH) receptors have not been found in the adrenal gland.
  • Our objective was to explore the relationship of LH with adrenal function in postmenopausal women, as assessed by 24-hour urinary free cortisol (UFC) and aldosterone excretion rate (AER).
  • We studied 36 postmenopausal women in sodium balance to control for variation in endogenous levels of plasma renin activity and angiotensin II.
  • Serum cortisol, aldosterone, LH, and FSH levels were measured, as were 24-hour UFC and AER.
  • RESULTS: Serum LH correlated significantly with log-transformed UFC (r = 0.43, P = 0.01) and inversely with log AER (r = -0.50, P = 0.002).
  • We found no correlation of serum LH with serum cortisol or aldosterone, nor did we find correlation of FSH with these parameters.
  • CONCLUSIONS: In postmenopausal women, serum LH levels correlate significantly with UFC (positively) and AER (negatively).
  • LH stimulation may induce subtle shifts in adrenal function toward cortisol secretion.
  • [MeSH-major] Adrenal Glands / physiology. Luteinizing Hormone / blood. Postmenopause / physiology
  • [MeSH-minor] Aged. Aldosterone / blood. Aldosterone / urine. Female. Follicle Stimulating Hormone / blood. Humans. Hydrocortisone / blood. Hydrocortisone / urine. Middle Aged

  • HSDB. structure - HYDROCORTISONE.
  • HSDB. structure - MENOTROPINS.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2391-6 [15671097.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1136-42 [16332935.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):875-81 [16728548.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3266-81 [18552288.001]
  • [Cites] Eur J Endocrinol. 2011 Mar;164(3):405-12 [21330483.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1577-81 [10564687.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3561-8 [11061502.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):230-7 [12519858.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):427-36 [12588201.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3279-84 [12865302.001]
  • [Cites] Am J Clin Pathol. 1977 Apr;67(4):318-23 [851092.001]
  • [Cites] Acta Endocrinol (Copenh). 1983 May;103(1):116-24 [6305073.001]
  • [Cites] Am Heart J. 1986 Feb;111(2):383-90 [3946178.001]
  • [Cites] Arch Pathol Lab Med. 1989 Sep;113(9):1071-5 [2549908.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Nov;69(5):1028-32 [2551915.001]
  • [Cites] Endocrinology. 1992 Jul;131(1):187-94 [1319318.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2397-400 [8964884.001]
  • [Cites] Genes Cells. 1997 Feb;2(2):95-106 [9167967.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Sep-Oct;63(1-3):17-9 [9449201.001]
  • [Cites] Hypertension. 1998 Feb;31(2):569-74 [9461223.001]
  • [Cites] Obstet Gynecol Clin North Am. 2004 Dec;31(4):817-35, x [15550337.001]
  • [Cites] Neth J Med. 2004 Dec;62(11):456-8 [15685898.001]
  • (PMID = 22713862.001).
  • [ISSN] 1530-0374
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD051959; United States / NICHD NIH HHS / HD / K12 HD051959-07; United States / NHLBI NIH HHS / HL / K24 HL096141; United States / NHLBI NIH HHS / HL / K24 HL096141-09; United States / NHLBI NIH HHS / HL / K24HL096141; United States / NCRR NIH HHS / RR / K30RR022292-07; United States / NCRR NIH HHS / RR / M01-RR02635; United States / NHLBI NIH HHS / HL / R01 HL67332; United States / NHLBI NIH HHS / HL / T32 HL007609; United States / NHLBI NIH HHS / HL / T32 HL007609-23; United States / NHLBI NIH HHS / HL / T32HL007609-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ NIHMS370573; NLM/ PMC3459175
  •  go-up   go-down


17. ||||||||.. 80%  Ishikawa M, Murai E, Hashiguchi Y, Iguchi T, Sato T: Effects of diethylstilbestrol on luteinizing hormone-producing cells in the mouse anterior pituitary. Exp Biol Med (Maywood); 2014 Mar;239(3):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of diethylstilbestrol on luteinizing hormone-producing cells in the mouse anterior pituitary.
  • Gonadotrophs in the anterior pituitary secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
  • Neonatal diethylstilbestrol (neoDES) treatment affects reproductive function of male and female mice, but the effect of this treatment on the development as well as direct effects on pituitary gonadotrophs have not been ascertained.
  • We investigated LH-secreting gonadotropes and the expression of genes involved in the synthesis and secretion of gonadotropins in the anterior pituitary of neoDES mice using immunohistochemistry and real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • The percentage of LH-secreting gonadotropes in 90-day-old female mice treated neonatally with an oil vehicle (neoOil) was significantly lower than in 30-day-old neoOil females but not in males, indicating a significant reduction after reproductive maturation in females.
  • The percentage of LH-secreting gonadotropes in the medial area of 90-day-old neoDES females was significantly lower than that of 90-day-old neoOil females, ovariectomized neoOil females, and neoOil and neoDES males.
  • The expression of the LH beta (Lhb) subunit in the anterior pituitary of 90-day-old neoDES females was similar to that in neoOil females, but it was significantly lower than that observed in 90-day-old males.
  • Ovariectomy increased the expression of the alpha subunit of glycoprotein hormones, FSH beta (Fshb) subunit and Lhb subunit both in neoOil and neoDES females, suggesting that the anterior pituitary of neoDES female mice is regulated by ovarian hormones via negative feedback.
  • In organ-cultured, anterior pituitaries exposed to DES exhibited no change in the number of LH-secreting gonadotropes but did reduced gene expression.
  • These results suggest that LH-secreting gonadotropes in the female mice are not only directly affected by neoDES but also are influenced by the masculinization of the hypothalamus.
  • However, the regulation of the pituitary gonadotropins by the hypothalamus could be different from that in intact male mice.
  • [MeSH-major] Carcinogens / pharmacology. Diethylstilbestrol / pharmacology. Gonadotrophs / drug effects. Gonadotrophs / metabolism. Luteinizing Hormone / metabolism. Pituitary Gland, Anterior / drug effects
  • [MeSH-minor] Animals. Female. Follicle Stimulating Hormone / biosynthesis. Follicle Stimulating Hormone / metabolism. Follicle Stimulating Hormone / secretion. Gene Expression. Hypothalamus / metabolism. Male. Mice. Mice, Inbred C57BL. Organ Culture Techniques. Pituitary Gland / metabolism

  • HSDB. structure - DIETHYLSTILBESTROL.
  • HSDB. structure - MENOTROPINS.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24521563.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 731DCA35BT / Diethylstilbestrol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  • [Keywords] NOTNLM ; Luteinizing hormone / anterior pituitary / diethylstilbestrol
  •  go-up   go-down


18. ||||||||.. 80%  Tundidor-Camba A, Caballero J, Coll D: 3D-QSAR modeling of non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor. Med Chem; 2013 Jun 1;9(4):560-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3D-QSAR modeling of non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor.
  • The application of ligand-based drug design methods such as quantitative structure-activity relationship (QSAR) is a mandatory issue in the design of luteinizing hormone-releasing hormone (LHRH) receptor antagonists because the lack of information on the molecular structure for this target protein.

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23072588.001).
  • [ISSN] 1875-6638
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Ligands; 0 / Pyridines; 0 / Pyrimidines; 0 / Receptors, LHRH; 0 / Sulfonamides
  •  go-up   go-down


19. ||||||||.. 77%  Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, Fu L, Qiao J: Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod Biol Endocrinol; 2012;10:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome.
  • BACKGROUND: High circulating luteinizing hormone (LH) level is a typical biochemical feature of polycystic ovary syndrome (PCOS) whose pathophysiology is still unclear.
  • Certain mutations of LH and LH receptor (LHR) may lead to changes in bioactivity of these hormones.
  • The aim of this study was determine the role of the LH and LHR polymorphisms in the pathogenesis of PCOS using a genetic approach.
  • METHODS: 315 PCOS women and 212 controls were screened for the gene variants of LH G1052A and LHR rs61996318 polymorphisms by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).
  • RESULTS: PCOS patients had significantly more A allele frequency of LH G1052A mutations than controls (p=0.001).
  • Within PCOS group, carriers of LH 1052A allele had lower LH (p=0.05) and higher fasting glucose levels (p=0.04).
  • CONCLUSIONS: Results suggested LH G1052A mutation might influence PCOS susceptibility and phenotypes.
  • [MeSH-major] Luteinizing Hormone / genetics. Polycystic Ovary Syndrome / genetics. Receptors, LH / genetics

  • Genetics Home Reference. consumer health - LHCGR Gene.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 1999 Aug;51(2):243-6 [10468997.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2011 Mar;46(3):177-80 [21575449.001]
  • [Cites] J Pediatr Endocrinol Metab. 2000;13 Suppl 5:1303-6 [11117675.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1318-23 [11238527.001]
  • [Cites] Fertil Steril. 2001 Jun;75(6):1238-9 [11384661.001]
  • [Cites] Endocr Rev. 2002 Apr;23(2):141-74 [11943741.001]
  • [Cites] Mol Hum Reprod. 2002 Oct;8(10):887-92 [12356936.001]
  • [Cites] Obstet Gynecol Surv. 2002 Nov;57(11):755-67 [12447098.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2242-9 [12727981.001]
  • [Cites] Hum Reprod. 2004 Jan;19(1):41-7 [14688154.001]
  • [Cites] Mol Hum Reprod. 2004 May;10(5):299-311 [15026540.001]
  • [Cites] J Clin Invest. 1976 May;57(5):1320-9 [770505.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] EMBO J. 1991 Jul;10(7):1885-90 [2050124.001]
  • [Cites] Hum Reprod. 1993 Nov;8 Suppl 2:123-8 [8276945.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1257-63 [7714098.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Sep;43(3):297-303 [7586598.001]
  • [Cites] Hum Hered. 1998 Jul-Aug;48(4):232-4 [9694256.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3984-91 [9814480.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1711-5 [10323405.001]
  • [Cites] Endocrine. 2005 Apr;26(3):207-17 [16034174.001]
  • [Cites] Reproduction. 2005 Sep;130(3):263-74 [16123233.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1470-6 [16464948.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2006 Dec;20(4):561-76 [17161332.001]
  • [Cites] Hum Reprod. 2007 Feb;22(2):401-6 [17099214.001]
  • [Cites] Lancet. 2007 Aug 25;370(9588):685-97 [17720020.001]
  • [Cites] Hum Reprod. 2009 Aug;24(8):2014-22 [19403562.001]
  • [Cites] Gynecol Endocrinol. 2009 Sep;25(9):603-9 [19591017.001]
  • [Cites] Prog Mol Biol Transl Sci. 2009;89:97-114 [20374734.001]
  • [Cites] Nat Genet. 2011 Jan;43(1):55-9 [21151128.001]
  • [Cites] Endocr Rev. 2000 Oct;21(5):551-83 [11041448.001]
  • (PMID = 22546001.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Receptors, LH; 9002-67-9 / Luteinizing Hormone
  • [Other-IDs] NLM/ PMC3403896
  •  go-up   go-down


20. ||||||||.. 77%  Arnhold IJ, Lofrano-Porto A, Latronico AC: Inactivating mutations of luteinizing hormone beta-subunit or luteinizing hormone receptor cause oligo-amenorrhea and infertility in women. Horm Res; 2009;71(2):75-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivating mutations of luteinizing hormone beta-subunit or luteinizing hormone receptor cause oligo-amenorrhea and infertility in women.
  • Women harbouring inactivating mutations in luteinizing hormone (LH) beta subunit (LHB) or LH receptor (LHCGR) genes have similar clinical manifestations characterized by female external genitalia, spontaneous breast and pubic hair development at puberty, and normal or late menarche followed by oligo-amenorrhea and infertility.
  • Oestradiol and progesterone levels are normal for the early to midfollicular phase, but do not reach ovulatory or luteal phase levels, confirming lack of ovulation.
  • Notably, serum LH levels are low in patients with LHB mutations and high in those with LHCGR mutations, whereas follicle-stimulating hormone levels are normal or only slightly increased.
  • Women with LHB mutations may be treated with hCG (human chorionic gonadotropin) or LH, whereas those with mutations in LHCGR are resistant.
  • Lhb and Lhcgr knockout female mice are close phenocopies of the respective human mutations, and confirm that early follicular development, low levels of oestrogen production and theca cell development are independent of LH action, which is necessary for ovulation.
  • [MeSH-major] Amenorrhea / genetics. Infertility, Female / genetics. Luteinizing Hormone, beta Subunit / genetics. Mutation. Receptors, LH / genetics
  • [MeSH-minor] Animals. Chorionic Gonadotropin / therapeutic use. Female. Hormone Replacement Therapy. Humans. Menstrual Cycle / blood. Menstrual Cycle / drug effects. Menstrual Cycle / genetics. Mice. Mice, Knockout


21. ||||||||.. 76%  Ogiwara K, Fujimori C, Rajapakse S, Takahashi T: Characterization of luteinizing hormone and luteinizing hormone receptor and their indispensable role in the ovulatory process of the medaka. PLoS One; 2013;8(1):e54482
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of luteinizing hormone and luteinizing hormone receptor and their indispensable role in the ovulatory process of the medaka.
  • The molecular properties and roles of luteinizing hormone (Lh) and its receptor (Lhcgrbb) have not been studied for the medaka (Oryzias latipes), which is an excellent animal model for ovulation studies.
  • Here, we characterized the medaka Lh/Lhcgrbb system, with attention to its involvement in the ovulatory process of this teleost fish.
  • In the medaka ovary, follicle-stimulating hormone receptor mRNA was expressed in small and medium-sized follicles, while lhcgrbb mRNA was expressed in the follicle layers of all growing follicles.
  • Experiments using HEK 293T cells expressing medaka Lhcgrbb in vitro revealed that gonadotropin from pregnant mare's serum and medaka recombinant Lh (rLh) bound to the fish Lhcgrbb.
  • The fish gonadotropin subunits Gtha, Fshb, and Lhb were essentially expressed at fairly constant levels in the pituitary of the fish during a 24-h spawning cycle.
  • This follicle culture method enabled us to determine that the Lh surge for the preovulatory follicle occurred in vivo between 19 and 15 h before ovulation.
  • These findings demonstrate that Lh/Lhcgrbb is critically involved in the induction of oocyte maturation and ovulation.
  • [MeSH-major] Luteinizing Hormone / genetics. Oryzias / physiology. Ovarian Follicle / physiology. Ovulation / genetics. RNA, Messenger / genetics. Receptors, LH / genetics
  • [MeSH-minor] Animals. Female. Gene Expression Regulation. Gonadotropins / pharmacology. HEK293 Cells. Humans. Matrix Metalloproteinase 15 / genetics. Matrix Metalloproteinase 15 / metabolism. Oocytes / cytology. Oocytes / physiology. Oviparity / physiology. Pituitary Gland / physiology. Protein Binding. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Tissue Culture Techniques

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8442-7 [15941829.001]
  • [Cites] Biol Reprod. 2001 Jan;64(1):382-9 [11133697.001]
  • [Cites] Reprod Biol Endocrinol. 2006;4:39 [16872517.001]
  • [Cites] Biol Reprod. 2007 Apr;76(4):692-700 [17192515.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7021-6 [17438297.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):714-9 [17554307.001]
  • [Cites] Mol Cell Endocrinol. 2007 Jun 30;272(1-2):63-76 [17543442.001]
  • [Cites] J Endocrinol. 2007 Aug;194(2):407-16 [17641288.001]
  • [Cites] J Endocrinol. 2007 Nov;195(2):213-28 [17951533.001]
  • [Cites] Mol Hum Reprod. 1999 Dec;5(12):1115-21 [10587365.001]
  • [Cites] Int J Dev Biol. 1999 Sep;43(6):541-54 [10610027.001]
  • [Cites] Mol Hum Reprod. 2000 Jan;6(1):11-8 [10611255.001]
  • [Cites] Eur J Biochem. 2000 Aug;267(15):4658-68 [10903498.001]
  • [Cites] Biol Reprod. 2003 Apr;68(4):1324-32 [12606486.001]
  • [Cites] Int Rev Cytol. 2003;225:131-85 [12696592.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):73-82 [14985246.001]
  • [Cites] Mech Dev. 2004 Jul;121(7-8):605-18 [15210170.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):5210-20 [15284199.001]
  • [Cites] J Exp Zool. 1978 Dec;206(3):355-63 [712347.001]
  • [Cites] Annu Rev Biochem. 1981;50:465-95 [6267989.001]
  • [Cites] Gen Comp Endocrinol. 1982 Oct;48(2):154-60 [6292040.001]
  • [Cites] Biol Reprod. 1990 Nov;43(5):818-27 [2291916.001]
  • [Cites] Biol Reprod. 1993 Apr;48(4):846-50 [7683501.001]
  • [Cites] Biol Reprod. 1994 Mar;50(3):629-42 [8167235.001]
  • [Cites] Chin J Biotechnol. 1993;9(4):247-55 [8061234.001]
  • [Cites] Biol Reprod. 1995 Mar;52(3):667-75 [7756460.001]
  • [Cites] Biol Reprod. 1995 Jun;52(6):1426-35 [7543299.001]
  • [Cites] Steroids. 1997 Jan;62(1):190-6 [9029736.001]
  • [Cites] Nature. 1997 Mar 20;386(6622):234 [9069280.001]
  • [Cites] Gen Comp Endocrinol. 1997 Nov;108(2):327-39 [9356228.001]
  • [Cites] Hum Reprod. 1999 Mar;14(3):642-9 [10221689.001]
  • [Cites] Biol Reprod. 1999 Jul;61(1):14-21 [10377026.001]
  • [Cites] Gen Comp Endocrinol. 1999 Aug;115(2):200-9 [10417233.001]
  • [Cites] Endocrinology. 1999 Sep;140(9):4351-8 [10465309.001]
  • [Cites] Biol Reprod. 2005 Mar;72(3):687-99 [15496514.001]
  • [Cites] Gen Comp Endocrinol. 2005 May 15;142(1-2):34-43 [15862546.001]
  • [Cites] Biol Reprod. 2005 Jun;72(6):1382-96 [15728794.001]
  • [Cites] Biol Reprod. 2005 Jun;72(6):1370-81 [15728795.001]
  • [Cites] Dev Growth Differ. 2008 Jun;50 Suppl 1:S195-219 [18482399.001]
  • [Cites] Gen Comp Endocrinol. 2008 Oct;159(1):46-57 [18722378.001]
  • [Cites] Biol Reprod. 2008 Nov;79(5):938-46 [18685126.001]
  • [Cites] Zoolog Sci. 2008 Sep;25(9):937-45 [19267604.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2009 May;153(1):44-8 [19152838.001]
  • [Cites] Gen Comp Endocrinol. 2009 Jun;162(2):192-202 [19327361.001]
  • [Cites] Gen Comp Endocrinol. 2010 Jan 1;165(1):144-54 [19539624.001]
  • [Cites] Gen Comp Endocrinol. 2010 Feb 1;165(3):367-89 [19505465.001]
  • [Cites] Gen Comp Endocrinol. 2010 Feb 1;165(3):412-37 [19686749.001]
  • [Cites] Endocrinology. 2010 May;151(5):2349-60 [20308533.001]
  • [Cites] Reprod Biol Endocrinol. 2010;8:34 [20385004.001]
  • [Cites] Cell Tissue Res. 2010 Jun;340(3):595-605 [20424863.001]
  • [Cites] Zoolog Sci. 2010 Sep;27(9):762-7 [20822405.001]
  • [Cites] Mol Cell Endocrinol. 2011 Jan 30;332(1-2):67-77 [20932877.001]
  • [Cites] Gen Comp Endocrinol. 2011 Mar 1;171(1):52-63 [21187099.001]
  • [Cites] Endocrinology. 2011 Nov;152(11):4418-30 [21878512.001]
  • [Cites] Biol Reprod. 2001 Jun;64(6):1633-43 [11369589.001]
  • [Cites] Rev Endocr Metab Disord. 2011 Dec;12(4):259-74 [21526415.001]
  • [Cites] Biol Reprod. 2012 Mar;86(3):93 [22174021.001]
  • [Cites] Biol Reprod. 2012 Apr;86(4):113 [22278979.001]
  • [Cites] Endocrinology. 2012 Jul;153(7):3394-404 [22544888.001]
  • [Cites] Mol Cell Endocrinol. 2012 Oct 15;362(1-2):76-84 [22659410.001]
  • [Cites] Mol Cell Endocrinol. 2012 Nov 25;364(1-2):89-100 [22954681.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Feb;290(2):R456-66 [16141306.001]
  • (PMID = 23372734.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadotropins; 0 / RNA, Messenger; 0 / Receptors, LH; 0 / Recombinant Proteins; 9002-67-9 / Luteinizing Hormone; EC 3.4.24.- / Matrix Metalloproteinase 15
  • [Other-IDs] NLM/ PMC3553140
  •  go-up   go-down


22. |||||||... 75%  Ma TH, Xiong QH, Yuan B, Jiang H, Gao Y, Xu JB, Liu SY, Ding Y, Zhang GL, Zhao YM, Zhang JB: Luteinizing hormone receptor splicing variants in bovine Leydig cells. Genet Mol Res; 2012;11(2):1721-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone receptor splicing variants in bovine Leydig cells.
  • The luteinizing hormone receptor (LHR) plays a key role in testosterone production through its interaction with the gonadotropins, LH and chorionic gonadotropin.
  • We examined the LHR splicing pattern in bovine Leydig cells; LH-induced expression of eight cloned splicing variants was detected by real-time PCR.
  • Luteinizing hormone applied to cultured Leydig cells resulted in expression of full-length LHR and the A and B isoforms, as well as secretion of testosterone, which first increased, then declined, and then increased further, with increased LH levels.
  • The secretion of testosterone progressively increased with increasing LH, but the expression levels of LHR (FL, A, and B) did not increase correspondingly.
  • We conclude that the LHR splicing pattern is complex in bovine Leydig cells, and that expression of full-length LHR and isoforms A and B changes when induced with LH.
  • [MeSH-major] Leydig Cells / metabolism. Receptors, LH / metabolism
  • [MeSH-minor] Alternative Splicing. Amino Acid Sequence. Analysis of Variance. Animals. Cattle. Cells, Cultured. Exons. Gene Expression. Luteinizing Hormone / physiology. Male. Molecular Sequence Data. Protein Isoforms / genetics. Protein Isoforms / metabolism. Testosterone / secretion

  • HSDB. structure - TESTOSTERONE.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22843048.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, LH; 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


23. |||||||... 75%  Bonger KM, van den Berg RJ, Knijnenburg AD, Heitman LH, van Koppen CJ, Timmers CM, Overkleeft HS, van der Marel GA: Discovery of selective luteinizing hormone receptor agonists using the bivalent ligand method. ChemMedChem; 2009 Jul;4(7):1189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of selective luteinizing hormone receptor agonists using the bivalent ligand method.
  • Biological evaluation revealed that both dimeric series exhibit unique biological properties relative to their monomeric counterparts.The luteinizing hormone receptor (LHR), the follicle-stimulating hormone receptor (FSHR), and the thyroid-stimulating hormone receptor (TSHR) belong to the glycoprotein hormone receptor (GpHR) family.
  • Recent developments in pro-fertility research have led to the discovery of several low-molecular-weight agonists for the luteinizing hormone/choriogonadotropin receptor that bind to the transmembrane (TM) region of the LHR.
  • [MeSH-major] Benzene / chemistry. Receptors, LH / agonists
  • [MeSH-minor] Drug Discovery. Ethylene Glycol / chemistry. Follicle Stimulating Hormone / agonists. Follicle Stimulating Hormone / metabolism. Ligands. Recombinant Proteins / agonists. Recombinant Proteins / metabolism. Structure-Activity Relationship

  • HSDB. structure - ETHYLENE GLYCOL.
  • HSDB. structure - BENZENE.
  • HSDB. structure - MENOTROPINS.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475639.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, LH; 0 / Recombinant Proteins; 9002-68-0 / Follicle Stimulating Hormone; FC72KVT52F / Ethylene Glycol; J64922108F / Benzene
  •  go-up   go-down


24. |||||||... 74%  Tomao E, Tomei G, Rosati MV, Caciari T, Danese D, Gamberale D, Vacca D, Palermo P, Anzelmo V, Tomei F: Luteinizing hormone (LH) levels in male workers exposed to urban stressors. Sci Total Environ; 2009 Aug 1;407(16):4591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone (LH) levels in male workers exposed to urban stressors.
  • The aim of the study is to evaluate if occupational exposure to urban stressors could cause alterations in luteinizing hormone (LH) plasma levels in male traffic policemen vs. administrative staff of Municipal Police.After excluding the subjects with the main confounding factors, male traffic police and administrative staff of Municipal Police were matched by age, working life, body mass index (BMI), alcohol drinking habit, cigarette smoking habit and habitual consumption of Italian coffee.In 166 male traffic police mean LH values were significantly higher compared to 166 male administrative employees.
  • The distribution of LH values in traffic police and in administrative employees was statistically significant.Our results suggest that recent exposure to urban stressors (chemical, physical and psycho-social) can alter the plasma concentration of LH.
  • In agreement with our previous research, levels of plasma LH may be used as early biological markers, valuable for the group, used in occupational set before the appearance of the disease.
  • [MeSH-major] Luteinizing Hormone / blood. Occupational Exposure / adverse effects. Police. Urban Population

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477485.001).
  • [ISSN] 1879-1026
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Air Pollutants; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


25. |||||||... 74%  Ni ZL, Zhang QH, Qu QY, Lü HL, Fan SY, Cai C: [Construction, expression and refolding of recombinant luteinizing hormone releasing hormone-angiogenin toxin]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug;45(8):680-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction, expression and refolding of recombinant luteinizing hormone releasing hormone-angiogenin toxin].
  • OBJECTIVE: To express, purify and refold recombinant luteinizing hormone releasing hormone-angiogenin (LHRH-Ang) toxin using E. coli. expression system.
  • METHODS: Recombinant LHRH-Ang expression vector was constructed by replacing of EGF fragment in plasmid pET28a/EGF-Ang with LHRH-PII fragment amplified from plasmid pET28/MSH-PE40.
  • Expression of recombinant LHRH-Ang toxin was induced by Isopropyl-β-D-Thiogalactoside (IPTG).
  • After IPGT induction, recombinant LHRH-Ang protein was expressed in BL21 (DE3) as inclusion body, it took 18.43% of total protein.
  • Recombinant LHRH-Ang toxin was refolded and concentrated by gradient dialysis and PEG 20000, respectively.
  • CONCLUSIONS: Recombinant LHRH-Ang protein was expressed in E. coli and refolded successfully.
  • [MeSH-major] Gonadotropin-Releasing Hormone / biosynthesis. Recombinant Fusion Proteins / biosynthesis. Ribonuclease, Pancreatic / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055247.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.1.27.- / angiogenin; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


26. |||||||... 74%  Hawken PA, Martin GB: Sociosexual stimuli and gonadotropin-releasing hormone/luteinizing hormone secretion in sheep and goats. Domest Anim Endocrinol; 2012 Aug;43(2):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sociosexual stimuli and gonadotropin-releasing hormone/luteinizing hormone secretion in sheep and goats.
  • Sheep and goats provide an ideal model to study the impact of sociosexual stimuli on the hypothalamic-pituitary-gonadal axis because we can use the robust changes in the pulsatile secretion of luteinizing hormone as a bioassay of gonadotropin-releasing hormone secretion.
  • [MeSH-major] Goats / physiology. Gonadotropin-Releasing Hormone / secretion. Luteinizing Hormone / secretion. Sexual Behavior, Animal / physiology. Sheep / physiology. Social Behavior

  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012. Published by Elsevier Inc.
  • (PMID = 22533940.001).
  • [ISSN] 1879-0054
  • [Journal-full-title] Domestic animal endocrinology
  • [ISO-abbreviation] Domest. Anim. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pheromones; 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


27. |||||||... 73%  Rahman NA, Rao CV: Recent progress in luteinizing hormone/human chorionic gonadotrophin hormone research. Mol Hum Reprod; 2009 Nov;15(11):703-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent progress in luteinizing hormone/human chorionic gonadotrophin hormone research.
  • The role of luteinizing hormone (LH) and human chorionic gonadotrophin hormone (hCG) in the regulation of normal reproductive functions in males and females is quite well established.
  • Besides the use of hCG in the development of diagnostic immunoassays, it has been successfully used in the induction of final follicular maturation and ovulation in the assisted reproductive technologies.
  • The basic and clinical research on the nongonadal actions of LH/hCG in the recent years has extended the potential of using these hormones in several clinical indications.
  • Hereby we will analyze the advances in the LH/hCG research (briefly emphasizing the nongonadal research), which has the potential for multiple novel therapies in reproductive and the other areas of medicine.
  • [MeSH-major] Chorionic Gonadotropin / physiology. Luteinizing Hormone / physiology
  • [MeSH-minor] Female. Humans. Male. Ovulation Induction. Reproduction / physiology. Reproductive Techniques, Assisted / trends

  • HSDB. structure - CHORIONIC GONADOTROPIN.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710244.001).
  • [ISSN] 1460-2407
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 9002-67-9 / Luteinizing Hormone
  • [Number-of-references] 111
  •  go-up   go-down


28. |||||||... 73%  Geng X, Ou X, Liao Y, Tan W, Wang S, Quan S: [Effect of basal serum luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome]. Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun;33(6):857-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of basal serum luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome].
  • OBJECTIVE: To evaluate the effect of basal serum luteinizing hormone (LH) and luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio on the clinical outcomes of in vitro fertilization-embryo transfer (IVF-ET) in patients with polycystic ovary syndrome (PCOS).
  • The cycles were classified into 2 groups according to serum levels of LH and also into 2 groups according to LH/FSH ratio, namely group A1 (LH≤10 IU/L), group A2 (LH>10 IU/L), group B1 (LH/FSH ratio<2), and group B2 (LH/FSH ratio≥2).
  • RESULTS: Patients in group A2 showed significantly higher FSH, T level, and LH/FSH ratio with a greater number of oocytes retrieved than those in group A1, but the time for down-regulation, duration of stimulation, AFC, LH and LH/FSH on the first day of stimulation, embryological data and pregnancy outcomes did not differ significantly between the two groups.
  • Compared with group B1, group B2 showed higher basal LH, E2 level on the day of HCG, more oocytes retrieved and lower dose of gonadotropins used, but the time for down-regulation, duration of stimulation, LH and LH/FSH on the first day of stimulation and pregnancy outcomes were comparable between the two groups.
  • CONCLUSION: A high basal LH level or a high LH/FSH ratio does not produce obvious deleterious effect on the clinical outcomes of IVF-ET in women with PCOS who take oral contraceptives for pretreatment before long GnRH-agonist protocol.
  • [MeSH-major] Follicle Stimulating Hormone / blood. Luteinizing Hormone / blood. Polycystic Ovary Syndrome / blood

  • Genetic Alliance. consumer health - Polycystic ovarian syndrome.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • HSDB. structure - MENOTROPINS.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23803197.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


29. |||||||... 73%  Al-Safi ZA, Roth L, Chosich J, Bradford A, Polotsky A, Santoro N: Elevated insulin in obese women relates to low endogenous luteinizing hormone. Obstet Gynecol; 2014 May;123 Suppl 1:95S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated insulin in obese women relates to low endogenous luteinizing hormone.
  • The physiology behind this is still unclear and may be the result of hypothalamic or pituitary factors or pharmacokinetics of gonadotropins.
  • We sought to investigate if insulin, directly or indirectly, suppresses pituitary luteinizing hormone (LH) secretion.
  • The study included 12 hours of unstimulated monitoring (to evaluate endogenous hypothalamic-pituitary function) with subsequent administration of intravenous bolus of gonadotropin-releasing hormone (to evaluate pituitary sensitivity).
  • Luteinizing hormone was measured with an immunofluorometric assay.
  • Luteinizing hormone pulsatility was evaluated using an objective, widely accepted method.
  • In the 2-hour postprandial period, there was a rise in insulin that was significantly higher (35.6 [17.1-54.1] compared with 16.5 [8.4-24.7] mU/L, P=.04) and LH that trended lower in the obese women (8.1 [3.5-12.7] compared with 4.2 [2.8-5.6] IU/L) ().(Figure is included in full-text article.
  • ) CONCLUSIONS: : Higher insulin in obese women may be associated with lower endogenous LH output.
  • A direct role of insulin in suppressing pituitary LH secretion should be further investigated.

  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24770310.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. |||||||... 73%  Lan KC, Chang SY, Huang FJ, Lin HJ, Lin CY, Huang KE, Kang HY: Analysis of androgen receptor and anti-Müllerian hormone pathways in human granulosa cells under luteinizing hormone treatment. Reprod Biol Endocrinol; 2013;11:11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of androgen receptor and anti-Müllerian hormone pathways in human granulosa cells under luteinizing hormone treatment.
  • BACKGROUND: The objective of this study was to determine the gene expression profiles of the androgen/androgen receptor (AR) and anti-Müllerian hormone (AMH)/ Sry-related high-mobility group box 9 (SOX9) pathways in granulosa-luteal cells from patients undergoing standard in vitro fertilization (IVF) with or without recombinant luteinizing hormone (rLH) therapy.
  • METHODS: Levels of reproductive hormones in the pre-ovulatory follicular fluid and the expression levels of LHR (luteinizing hormone receptor), AR, SOX9, AMH, AR-associated protein 54(ARA54)and ARA70 were determined in granulosa-luteal cells by real-time reverse-transcription PCR.
  • The effects of androgen and rLH treatments on AR and AMH expression levels were also tested in vitro using HO23 cells.
  • RESULTS: We collected 35 an 70 granulosa cell samples from patients cycled with and without rLH supplementation, respectively.
  • The clinical outcomes were similar in patients who received rLH therapy and those who did not, though the pre-ovulatory follicular fluid levels of androstenedione, testosterone, and estradiol were significantly higher and progesterone was lower in the rLH supplementation group.
  • Moreover, granulosa-luteal cell mRNA levels of LHR, AR, AMH, and SOX9 were significantly higher in the rLH supplementation group relative to the group that did not receive rLH supplementation.
  • [MeSH-major] Anti-Mullerian Hormone / physiology. Granulosa Cells / metabolism. Luteinizing Hormone / physiology. Luteinizing Hormone / therapeutic use. Receptors, Androgen / biosynthesis. SOX9 Transcription Factor / biosynthesis. Signal Transduction / physiology
  • [MeSH-minor] Adult. Case-Control Studies. Cell Line, Transformed. Cells, Cultured. Female. Fertilization in Vitro / methods. Humans. Infertility, Female / metabolism. Infertility, Female / therapy. Treatment Outcome

  • Genetics Home Reference. consumer health - AMH Gene.
  • Genetics Home Reference. consumer health - AR Gene.
  • Genetics Home Reference. consumer health - LHCGR Gene.
  • Genetics Home Reference. consumer health - SOX9 Gene.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 2000 Mar;217(3):293-8 [10741423.001]
  • [Cites] Reprod Biomed Online. 2006 Apr;12(4):415-7 [16740212.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):595-600 [11750735.001]
  • [Cites] Fertil Steril. 2008 Dec;90(6):2203-10 [18291376.001]
  • [Cites] Reprod Biomed Online. 2009;18 Suppl 2:31-6 [19406029.001]
  • [Cites] Reprod Biol Endocrinol. 2009;7:58 [19497101.001]
  • [Cites] Hum Reprod Update. 2010 Mar-Apr;16(2):113-30 [19793843.001]
  • [Cites] Reprod Biomed Online. 2010 Mar;20(3):350-7 [20093082.001]
  • [Cites] Reprod Biol Endocrinol. 2010;8:25 [20226040.001]
  • [Cites] Fertil Steril. 2010 May 1;93(7):2269-73 [19200958.001]
  • [Cites] Reproduction. 2006 Aug;132(2):191-206 [16885529.001]
  • [Cites] Hum Reprod. 2007 Mar;22(3):676-87 [17110397.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD005070 [17443569.001]
  • [Cites] Hum Reprod Update. 2007 Sep-Oct;13(5):445-52 [17586849.001]
  • [Cites] Fertil Steril. 2008 Jun;89(6):1760-5 [17628551.001]
  • [Cites] Mol Hum Reprod. 2010 Sep;16(9):637-43 [20064870.001]
  • [Cites] Biol Reprod. 2010 Oct;83(4):514-24 [20592308.001]
  • [Cites] Mol Hum Reprod. 2011 Jan;17(1):63-70 [20843821.001]
  • [Cites] Reprod Biomed Online. 2011 Jul;23(1):81-90 [21550853.001]
  • [Cites] Hum Reprod. 2012 Jan;27(1):244-50 [22095792.001]
  • [Cites] Int J Biostat. 2009;5(1):Article 1 [20231866.001]
  • [Cites] Reprod Biomed Online. 2012 Mar;24(3):261-71 [22285265.001]
  • [Cites] Mol Cell Endocrinol. 2012 Jun 5;356(1-2):48-54 [21846490.001]
  • [Cites] Fertil Steril. 2012 May;97(5):1108-14.e1 [22365075.001]
  • [Cites] Fertil Steril. 2012 Jul;98(1):e10-1; author reply e12 [22633649.001]
  • [Cites] J Assist Reprod Genet. 2012 Sep;29(9):869-75 [22644636.001]
  • [Cites] J Endocrinol. 2002 Mar;172(3):557-63 [11874704.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1156-61 [11889180.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2178-80 [12077402.001]
  • [Cites] Reprod Biomed Online. 2002 Sep-Oct;5(2):104-8 [12419032.001]
  • [Cites] Hum Reprod Update. 2002 Nov-Dec;8(6):543-57 [12498424.001]
  • [Cites] Chang Gung Med J. 2003 Jun;26(6):388-402 [12956285.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 15;211(1-2):21-31 [14656472.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5957-62 [14671196.001]
  • [Cites] Mol Hum Reprod. 2004 Feb;10(2):77-83 [14742691.001]
  • [Cites] Hum Reprod Update. 2004 Mar-Apr;10(2):107-17 [15073141.001]
  • [Cites] Reprod Biomed Online. 2004 May;8(5):516-23 [15151712.001]
  • [Cites] Endocr Rev. 1985 Summer;6(3):371-99 [3896767.001]
  • [Cites] Endocrinology. 1993 Nov;133(5):2204-12 [8404672.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6653-65 [9774680.001]
  • [Cites] Endocrinology. 1998 Nov;139(11):4679-87 [9794480.001]
  • [Cites] Hum Reprod. 2004 Dec;19(12):2869-74 [15471935.001]
  • [Cites] Fertil Steril. 2005 Apr;83 Suppl 1:1241-7 [15831298.001]
  • [Cites] Hum Reprod. 2000 Nov;15(11):2258-65 [11056116.001]
  • (PMID = 23433069.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human; 80497-65-0 / Anti-Mullerian Hormone; 9002-67-9 / Luteinizing Hormone
  • [Other-IDs] NLM/ PMC3599510
  •  go-up   go-down


31. |||||||... 73%  Moradi SV, Mansfeld FM, Toth I: Synthesis and in vitro evaluation of glycosyl derivatives of luteinizing hormone-releasing hormone (LHRH). Bioorg Med Chem; 2013 Jul 15;21(14):4259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and in vitro evaluation of glycosyl derivatives of luteinizing hormone-releasing hormone (LHRH).
  • Luteinizing hormone-releasing hormone (LHRH) analogues are used extensively for the treatment of various hormone-dependent diseases.
  • Modification of peptide sequences by attachment of carbohydrate moieties is a promising strategy that may increase the metabolic stability of the target peptide and enhance its transport across cell membranes, subsequently improving peptide bioavailability.
  • [MeSH-major] Gonadotropin-Releasing Hormone / chemical synthesis. Gonadotropin-Releasing Hormone / pharmacology
  • [MeSH-minor] Caco-2 Cells. Cell Membrane Permeability / drug effects. Drug Stability. Glycosylation. Humans. Molecular Structure. Small Molecule Libraries / chemical synthesis. Small Molecule Libraries / chemistry. Small Molecule Libraries / pharmacokinetics

  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Elsevier Ltd. All rights reserved.
  • (PMID = 23712085.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Small Molecule Libraries; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


32. |||||||... 73%  Kim DJ, Kawazoe I, Jung JH, An CM, Kim YC, Aida K: Purification and characterization of luteinizing hormone from pituitary glands of rockfish, Sebastes schlegeli. Comp Biochem Physiol B Biochem Mol Biol; 2011 Oct;160(2-3):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterization of luteinizing hormone from pituitary glands of rockfish, Sebastes schlegeli.
  • To acquire greater knowledge of the reproductive function of luteinizing hormone (LH) in the viviparous rockfish Sebastes schlegeli, LH from the pituitary glands of mature rockfish was isolated, purified, and localized and its biological activity was characterized.
  • The molecular mass of purified LH was estimated to be approximately 33 kDa, similar to that of known LH.
  • When rockfish LH was purified by reverse-phase high-performance liquid chromatography, its N-terminal amino acid sequences were found to coincide with those of predicted cDNA sequences of rockfish gonadotropin α (ssGTHα) and ssLHβ mature peptides.
  • Immunocytochemical analysis using antisera against ssGTHα (molecular weight [MW], ~14.5 kDa) and ssLHβ (MW, ~18.5 kDa) indicated that the LH-producing cells are mainly distributed throughout the proximal pars distalis and along the periphery of the pars intermedia.
  • Further, in vitro ovarian follicle analysis demonstrated that purified intact rockfish LH significantly enhances E(2) secretion in a dose-dependent manner.
  • This is the first report on the purification and characterization of LH from a viviparous teleost, and these results will enable future research and increase our understanding of the mechanisms underlying the maturation of such fish.
  • [MeSH-major] Luteinizing Hormone / isolation & purification. Luteinizing Hormone / metabolism. Perciformes / anatomy & histology. Perciformes / metabolism. Pituitary Gland / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Inc. All rights reserved.
  • (PMID = 21791250.001).
  • [ISSN] 1879-1107
  • [Journal-full-title] Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology
  • [ISO-abbreviation] Comp. Biochem. Physiol. B, Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


33. |||||||... 73%  Ogata R, Matsuzaki T, Iwasa T, Kiyokawa M, Tanaka N, Kuwahara A, Yasui T, Irahara M: Hypothalamic Ghrelin suppresses pulsatile secretion of luteinizing hormone via beta-endorphin in ovariectomized rats. Neuroendocrinology; 2009;90(4):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypothalamic Ghrelin suppresses pulsatile secretion of luteinizing hormone via beta-endorphin in ovariectomized rats.
  • OBJECTIVES: Ghrelin, an endogenous growth hormone secretagogue, is a known accelerator of feeding behavior and suppresses pulsatile secretion of luteinizing hormone (LH) in ovariectomized rats.
  • We examined the effects of naloxone (NAL), a specific opioid antagonist, on the suppression of pulsatile LH secretion by ghrelin to determine whether beta-endorphin (beta-END) is involved in this suppressive effect.
  • METHODS: Ghrelin was administered intracerebroventricularly, and NAL was injected intravenously in ovariectomized rats; then, serum LH concentrations were measured by radioimmunoassay in blood samples drawn every 6 min for 2 h to analyze pulsatile secretion.
  • RESULTS: Administration of ghrelin significantly reduced mean LH concentration and pulse frequency.
  • Coadministration of NAL with ghrelin significantly restored mean LH concentration and pulse frequency.
  • CONCLUSION: Suppressive effect of intracerebroventricular injection of ghrelin on pulsatile LH secretion was mediated by beta-END, suggesting that hypothalamic ghrelin suppressed pulsatile gonadotropin-releasing hormone secretion via beta-END in female rats.
  • [MeSH-major] Ghrelin / metabolism. Hypothalamus / physiology. Luteinizing Hormone / secretion. beta-Endorphin / metabolism

  • HSDB. structure - NALOXONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19907132.001).
  • [ISSN] 1423-0194
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Narcotic Antagonists; 36B82AMQ7N / Naloxone; 60617-12-1 / beta-Endorphin; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


34. |||||||... 73%  Toporcerová S, Urdzík P, Popelková M, Balasicová K, Ostró A: [The impact of exogenous luteinizing hormone on IVF/ICSI cycles parameters]. Ceska Gynekol; 2011 Sep;76(4):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The impact of exogenous luteinizing hormone on IVF/ICSI cycles parameters].
  • OBJECTIVE: To evaluate the effect of exogenous luteinizing hormone on IVF/ICSI success.
  • RESULTS: There was no statistically significant difference in IVF/ICSI success between individual groups and subgroups, but we demonstrated the increase in clinical pregnancy rate per ET in agonist cycles group with exogenous LH activity totally above 11% (27.6% vs. 38.6%), in patients under 35 years above 12% (30.4% vs. 42.6%) and in patients over 35 years above 14% (16.7% vs. 30.8%).
  • CONCLUSIONS: Despite of negative statistical analyses, from the clinical point of view we can strongly recommend the LH addition during COH, especially in agonist cycles and in older women.
  • [MeSH-major] Fertilization in Vitro. Luteinizing Hormone / administration & dosage. Sperm Injections, Intracytoplasmic
  • [MeSH-minor] Adult. Embryo Transfer. Female. Follicle Stimulating Hormone / administration & dosage. Gonadotropin-Releasing Hormone / agonists. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Humans. Pregnancy

  • HSDB. structure - MENOTROPINS.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22026067.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceská gynekologie / Ceská lékarská spolecnost J. Ev. Purkyne
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


35. |||||||... 73%  Zhang Z, Liao H, Chen X, Zheng Y, Liu Y, Tao X, Gu C, Dong L, Duan T, Yang Y, Liu X, Yu Y, Feng Y: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol; 2011 Mar;155(1):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors.
  • OBJECTIVE: Luteinizing hormone (LH) plays an important role in the development of ovarian cancer, and has been shown to inhibit apoptosis in ovarian cancer cells.
  • Therefore, the aim of this study was to determine whether survivin can be induced by LH in ovarian cancer, and whether this induction influences the sensitivity of ovarian cancers to chemotherapy.
  • STUDY DESIGN: Survivin expression was monitored using western blot assays, and flow cytometry was used to detect the effects of cisplatin on the induction of apoptosis by LH.
  • MTT assays were also used to analyze rates of cell proliferation.
  • RESULTS: Administration of LH in vitro induced survivin expression in a dose-dependent manner.
  • LH also blocked apoptosis induced by cisplatin.
  • CONCLUSION: These results suggest that LH influences the sensitivity of ovarian cancer cells to chemotherapy via signaling to inhibit apoptosis that also upregulates survivin.
  • [MeSH-major] Apoptosis. Inhibitor of Apoptosis Proteins / metabolism. Luteinizing Hormone / physiology. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Up-Regulation
  • [MeSH-minor] Antineoplastic Agents / antagonists & inhibitors. Antineoplastic Agents / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Cell Proliferation. Cell Survival. Cisplatin / antagonists & inhibitors. Cisplatin / pharmacology. Drug Resistance, Neoplasm. Female. Humans. MAP Kinase Signaling System / drug effects. Molecular Targeted Therapy. Osmolar Concentration. Protein Kinase Inhibitors / pharmacology. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • HSDB. structure - CIS-DIAMINEDICHLOROPLATINUM.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 21074309.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 9002-67-9 / Luteinizing Hormone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. |||||||... 73%  Du JW, Xu KY, Fang LY, Qi XL: Association between mutations of the luteinizing hormone β subunit and female infertility. Mol Med Rep; 2012 Feb;5(2):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between mutations of the luteinizing hormone β subunit and female infertility.
  • To explore the association between mutations of Trp8Arg and Ile15Thr in the luteinizing hormone (LH) gene and female infertility, primary female infertility patients (n=60) and normal healthy women (n=60) were screened for mutations Trp8Arg and Ile15Thr in the LH-β subunit gene by polymerase chain reaction-restriction fragment length polymorphism, and associations were examined between the mutations and female infertility.
  • A significant difference was noted in the LH level among women with different genotypes (P<0.05), and the LH level was highest in women who were homozygous for both mutations.
  • However, there were no significant differences in FSH level and FSH/LH ratio among subjects with different genotypes (P>0.05).
  • In conclusion, polymorphisms of Trp8Arg and Ile15Thr in the LH-β subunit gene occur in infertile women.
  • [MeSH-major] Infertility, Female / genetics. Luteinizing Hormone, beta Subunit / genetics. Mutation
  • [MeSH-minor] Adult. Alleles. Amino Acid Substitution. Female. Follicle Stimulating Hormone / analysis. Gene Frequency. Genotype. Homozygote. Humans. Polymorphism, Single Nucleotide. Risk Factors

  • Genetic Alliance. consumer health - infertility.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • HSDB. structure - MENOTROPINS.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22108961.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Luteinizing Hormone, beta Subunit; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


37. |||||||... 72%  Yao JF, Zhou N, Lv YJ, Zhang R, Liu KL, Xue M: Metabolic stability of long-acting luteinizing hormone-releasing hormone antagonists. Amino Acids; 2012 Oct;43(4):1557-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic stability of long-acting luteinizing hormone-releasing hormone antagonists.
  • Long-acting luteinizing hormone-releasing hormone (LHRH) antagonists designed to be protease resistant consisted of a series of novel decapeptides structurally similar to LHRH.
  • [MeSH-major] Gonadotropin-Releasing Hormone / antagonists & inhibitors. Kidney / chemistry. Liver / chemistry. Lung / chemistry. Oligopeptides / chemical synthesis

  • HSDB. structure - PANCREATIN.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22327511.001).
  • [ISSN] 1438-2199
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / Tissue Extracts; 33515-09-2 / Gonadotropin-Releasing Hormone; 8049-47-6 / Pancreatin
  •  go-up   go-down


38. |||||||... 72%  Barb CR, Hausman GJ, Kraeling RR: Luteinizing hormone secretion as influenced by age and estradiol in the prepubertal gilt. Anim Reprod Sci; 2010 Dec;122(3-4):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone secretion as influenced by age and estradiol in the prepubertal gilt.
  • The aim of this study was to determine if there is an age related reduction in the sensitivity of the negative feedback action of 17β-estradiol (estradiol) on luteinizing hormone (LH) secretion in the prepubertal gilt.
  • On Day 10 blood samples were collected every 15 min for 8h and serum LH and estradiol concentrations were measured.
  • Serum estradiol concentrations averaged 5 ± 1, 5 ± 1 and 7 ± 2 pg/ml for the 90-, 150- and 210-day-old gilts implanted with estradiol, respectively, whereas, serum estradiol concentrations was undetectable in C gilts.
  • Mean serum LH concentrations, basal LH concentrations and serum LH pulse amplitude were less in EB-treated gilts at all ages compared to control animals.
  • In contrast, LH pulse frequency initially was less in EB-treated gilts but subsequently increased (P<0.04) with age (from 0.8 ± 0.2 at 90 days to 5.2 ± 0.2/8h at 210 days), and at 210 days of age the pulse frequency was similar to C gilts.
  • These results demonstrate an age related reduction in the sensitivity to the negative feedback action of estradiol on LH secretion and support the idea that the gilt conforms to the gonadostat hypothesis.
  • [MeSH-major] Aging / physiology. Estradiol / physiology. Luteinizing Hormone / secretion. Swine / physiology

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • HSDB. structure - ESTRADIOL.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 21055887.001).
  • [ISSN] 1873-2232
  • [Journal-full-title] Animal reproduction science
  • [ISO-abbreviation] Anim. Reprod. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 1S4CJB5ZGN / estradiol 3-benzoate; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


39. |||||||... 72%  Ginther OJ, Fuenzalida MJ, Shrestha HK, Beg MA: Concomitance of luteinizing hormone and progesterone oscillations during the transition from preluteolysis to luteolysis in cattle. Domest Anim Endocrinol; 2011 Feb;40(2):77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitance of luteinizing hormone and progesterone oscillations during the transition from preluteolysis to luteolysis in cattle.
  • The temporal relationships of episodes of luteinizing hormone (LH) oscillations, 13,14-dihydro-15-keto-PGF2α (PGFM) pulses, and progesterone (P4) fluctuations during the latter portion of preluteolysis and the early portion of luteolysis were characterized.
  • In Experiment 1, the detection of LH episodes in blood samples collected every 15 min for 8 h was compared with detection in the samples collected every hour in 4 heifers.
  • During preluteolysis, compared with luteolysis, the amplitude of LH oscillations was greater (0.28 ± 0.03 vs 0.18 ± 0.03 ng/mL; P < 0.02) and the interval between peaks of LH oscillations was shorter (3.3 ± 0.3 h vs 4.3 ± 0.6 h; P < 0.04).
  • The LH peaks occurred at the same hour as the peak of a P4 fluctuation in 77% and 29% of LH oscillations (P < 0.0009) during preluteolysis and luteolysis, respectively.
  • In preluteolysis, synchrony between LH and P4 episodes occurred consistently during the P4 rebound after the peak of a PGFM pulse.
  • In luteolysis, the LH peak preceded the peak of the P4 rebound.
  • On a temporal basis, the hypothesis was supported that episodic LH accounts, at least in part, for the reported P4 rebound that occurs after the P4 suppression at the peak of a PGFM pulse.
  • [MeSH-major] Dinoprost / analogs & derivatives. Estradiol / blood. Luteinizing Hormone / blood. Luteolysis / blood. Progesterone / blood

  • HSDB. structure - ESTRADIOL.
  • HSDB. structure - PROSTAGLANDIN F2ALPHA.
  • HSDB. structure - PROGESTERONE.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Inc. All rights reserved.
  • (PMID = 21093198.001).
  • [ISSN] 1879-0054
  • [Journal-full-title] Domestic animal endocrinology
  • [ISO-abbreviation] Domest. Anim. Endocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 27376-76-7 / 15-keto-13,14-dihydroprostaglandin F2alpha; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; B7IN85G1HY / Dinoprost
  •  go-up   go-down


40. |||||||... 72%  Wagenmaker ER, Breen KM, Oakley AE, Pierce BN, Tilbrook AJ, Turner AI, Karsch FJ: Cortisol interferes with the estradiol-induced surge of luteinizing hormone in the ewe. Biol Reprod; 2009 Mar;80(3):458-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortisol interferes with the estradiol-induced surge of luteinizing hormone in the ewe.
  • Two experiments were conducted to test the hypothesis that cortisol interferes with the positive feedback action of estradiol that induces the luteinizing hormone (LH) surge.
  • Cortisol or vehicle (saline) was infused from 2 h before the estradiol stimulus through the time of the anticipated LH surge in the artificial follicular phase of two successive cycles.
  • All ewes responded with an LH surge.
  • Cortisol delayed the LH surge and reduced its amplitude, but both effects were observed only in the second cycle.
  • Again, cortisol delayed but did not block the LH surge, and this delay occurred in both cycles.
  • Thus, an elevation in plasma cortisol can interfere with the positive feedback action of estradiol by delaying and attenuating the LH surge.
  • [MeSH-major] Estradiol / pharmacology. Estrus / blood. Feedback, Physiological / physiology. Hydrocortisone / blood. Luteinizing Hormone / blood

  • HSDB. structure - HYDROCORTISONE.
  • HSDB. structure - ESTRADIOL.
  • HSDB. structure - PROGESTERONE.
  • COS Scholar Universe. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2004 Feb;145(2):692-8 [14576178.001]
  • [Cites] Domest Anim Endocrinol. 2009 May;36(4):202-8 [19185443.001]
  • [Cites] Biol Reprod. 2000 Jan;62(1):45-53 [10611066.001]
  • [Cites] Endocr Rev. 2000 Feb;21(1):55-89 [10696570.001]
  • [Cites] Endocrinology. 2000 Mar;141(3):1050-8 [10698181.001]
  • [Cites] Rev Reprod. 2000 May;5(2):105-13 [10864855.001]
  • [Cites] Anim Reprod Sci. 2000 Nov 1;63(3-4):167-75 [10989227.001]
  • [Cites] Biol Reprod. 2000 Oct;63(4):1135-42 [10993837.001]
  • [Cites] Theriogenology. 2001 Jan 15;55(2):573-92 [11233784.001]
  • [Cites] Endocrinology. 2001 May;142(5):1915-22 [11316757.001]
  • [Cites] Brain Res. 2002 Aug 9;946(1):79-86 [12133597.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):3748-58 [12239084.001]
  • [Cites] Biol Reprod. 2002 Nov;67(5):1605-12 [12390894.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):221-7 [14551234.001]
  • [Cites] Fertil Steril. 1967 May-Jun;18(3):297-302 [6067235.001]
  • [Cites] Fertil Steril. 1969 Mar-Apr;20(2):223-31 [5767267.001]
  • [Cites] Endocrinology. 1969 May;84(5):1166-73 [5813408.001]
  • [Cites] Endocrinology. 1974 May;94(5):1397-403 [4823516.001]
  • [Cites] Endocrinology. 1977 Sep;101(3):807-17 [560959.001]
  • [Cites] Endocrinology. 1979 Jul;105(1):120-8 [376294.001]
  • [Cites] J Endocrinol. 1981 May;89(2):229-40 [7195422.001]
  • [Cites] J Endocrinol. 1981 Aug;90(2):221-5 [7196432.001]
  • [Cites] J Med Chem. 1988 Jun;31(6):1160-9 [2897467.001]
  • [Cites] Neuroendocrinology. 1988 Sep;48(3):296-303 [3054617.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):127-34 [2671236.001]
  • [Cites] Endocrinology. 1990 Sep;127(3):1375-84 [2201536.001]
  • [Cites] Endocrinology. 1990 Sep;127(3):1470-6 [2201538.001]
  • [Cites] J Neuroendocrinol. 1993 Aug;5(4):445-50 [8401568.001]
  • [Cites] J Endocrinol. 1994 Sep;142(3):447-51 [7964295.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5511-9 [7588302.001]
  • [Cites] Life Sci. 1997;60(10):735-42 [9064478.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4273-81 [9322940.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5408-14 [9389526.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):588-95 [9449629.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):269-301 [9626555.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2454-60 [9661628.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2471-9 [10342831.001]
  • [Cites] J Reprod Fertil. 1999 May;116(1):1-8 [10505050.001]
  • [Cites] J Reprod Fertil. 1999 May;116(1):9-18 [10505051.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):2107-15 [15625239.001]
  • [Cites] Biol Reprod. 2006 Jan;74(1):41-5 [16148215.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1882-90 [17204556.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E270-6 [17405827.001]
  • [Cites] Endocrinology. 2008 Feb;149(2):767-73 [17962347.001]
  • [Cites] Horm Behav. 2008 Aug;54(3):424-34 [18519136.001]
  • [Cites] Endocrinology. 2009 Jan;150(1):341-9 [18801903.001]
  • [Cites] Neuroendocrinology. 2009;89(1):86-97 [18714145.001]
  • [Cites] Neuroimmunomodulation. 2000;7(1):6-15 [10601814.001]
  • (PMID = 19056703.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD30773; United States / PHS HHS / / T32-07048; United States / PHS HHS / / T32-08322
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endotoxins; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2805396
  •  go-up   go-down


41. |||||||... 72%  Dufau ML, Liao M, Zhang Y: Participation of signaling pathways in the derepression of luteinizing hormone receptor transcription. Mol Cell Endocrinol; 2010 Jan 27;314(2):221-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Participation of signaling pathways in the derepression of luteinizing hormone receptor transcription.
  • The luteinizing hormone receptor (LHR) transcription is subject to an epigenetic regulatory mode whereby the proximal Sp1 site acts as an anchor to recruit histone deacetylases (HDAC)1/2 and the Sin3A co-repressor complex.
  • The HDAC inhibitor TSA-induced cell-specific phosphatase release from the promoter, which serves as an 'on' mechanism for Sp1 phosphorylation by phosphatidylinositol 3-kinase/protein kinase Czeta (PI3K/PKCzeta) at Ser641, leading to p107 repressor derecruitment and LHR transcriptional activation.
  • The methylation status of the promoter provides another layer of modulation in a cell-specific manner.
  • Collectively, these findings demonstrate that LHR gene expression at the transcriptional level is regulated by complex and diverse networks, in which coordination and interactions between these regulatory effectors are crucial for silencing/activation of LHR expression.
  • [MeSH-major] Receptors, LH / genetics. Signal Transduction / genetics. Transcription, Genetic / genetics

  • Genetics Home Reference. consumer health - LHCGR Gene.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Biol Reprod. 1997 Nov;57(5):1202-10 [9369188.001]
  • [Cites] Recent Prog Horm Res. 1995;50:223-54 [7740159.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):366-71 [10491299.001]
  • [Cites] Trends Endocrinol Metab. 2005 Sep;16(7):320-6 [16054836.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):7929-39 [16135786.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6748-61 [16943418.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):283-91 [7626469.001]
  • [Cites] J Biol Chem. 1996 Jul 12;271(28):16764-72 [8663226.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31813-7 [8943222.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):857-64 [9041186.001]
  • [Cites] Mol Endocrinol. 2008 Jun;22(6):1449-63 [18372343.001]
  • [Cites] J Biol Chem. 2008 Aug 29;283(35):24039-46 [18596044.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2763-70 [10644740.001]
  • [Cites] Mol Endocrinol. 2000 Sep;14(9):1498-508 [10976926.001]
  • [Cites] Endocrinology. 2001 May;142(5):2013-21 [11316768.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1891-905 [11682620.001]
  • [Cites] Fertil Steril. 2001 Dec;76(6):1097-100 [11730733.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33431-8 [12091390.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4718-29 [12446600.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6958-72 [12972613.001]
  • [Cites] Vitam Horm. 2004;68:1-48 [15193450.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):4119-23 [15292356.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Aug;74(8):3419-23 [198785.001]
  • [Cites] Recent Prog Horm Res. 1980;36:557-662 [6251521.001]
  • [Cites] Annu Rev Physiol. 1988;50:441-63 [3288100.001]
  • [Cites] Science. 1989 Aug 4;245(4917):494-9 [2502842.001]
  • [Cites] Science. 1989 Aug 4;245(4917):525-8 [2502844.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Feb;70(2):421-30 [1688865.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Nov 15;172(3):1049-54 [2244890.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19385-8 [2174034.001]
  • [Cites] Endocrinology. 1991 May;128(5):2297-308 [2019252.001]
  • [Cites] J Biol Chem. 1991 Jun 15;266(17):11355-9 [2040640.001]
  • [Cites] J Biol Chem. 1992 Mar 5;267(7):4479-88 [1311310.001]
  • [Cites] Mol Endocrinol. 1992 Mar;6(3):320-6 [1316538.001]
  • [Cites] Mol Cell Endocrinol. 1992 Oct;88(1-3):55-66 [1459341.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4447-52 [8440726.001]
  • [Cites] Endocrinology. 1993 May;132(5):2262-70 [8477671.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15868-75 [8195242.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):307-15 [8027246.001]
  • [Cites] Endocrinology. 1995 Mar;136(3):917-23 [7867600.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7487-94 [7706295.001]
  • [Cites] Annu Rev Physiol. 1998;60:461-96 [9558473.001]
  • (PMID = 19464346.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / Z01 HD000150-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Histones; 0 / Receptors, LH; 0 / Repressor Proteins
  • [Number-of-references] 45
  • [Other-IDs] NLM/ NIHMS119226; NLM/ PMC2815110
  •  go-up   go-down


42. |||||||... 72%  Laimou D, Katsila T, Matsoukas J, Schally A, Gkountelias K, Liapakis G, Tamvakopoulos C, Tselios T: Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties. Eur J Med Chem; 2012 Dec;58:237-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties.
  • This article describes the rational design, synthesis and pharmacological properties of amide-linked cyclic analogues of Luteinizing Hormone-Releasing Hormone (LHRH) with substitutions at positions 1 (Pro), 6 (D-Leu/D-Trp), 9 (Aze) and 10 (BABA/Acp).
  • [MeSH-major] Drug Design. Gonadotropin-Releasing Hormone / chemical synthesis

  • HSDB. structure - CETRORELIX.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier Masson SAS. All rights reserved.
  • (PMID = 23127987.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amides; 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone; OON1HFZ4BA / cetrorelix
  •  go-up   go-down


43. |||||||... 72%  Lee HS, Park HK, Ko JH, Kim YJ, Hwang JS: Utility of Basal luteinizing hormone levels for detecting central precocious puberty in girls. Horm Metab Res; 2012 Oct;44(11):851-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of Basal luteinizing hormone levels for detecting central precocious puberty in girls.
  • The hallmark of puberty is the progressive increase in gonadotropin-releasing hormone (GnRH) activity, reflected by an increase in the circulating concentration of luteinizing hormone (LH).
  • The GnRH stimulation test is widely used in the evaluation of precocious puberty.
  • The aim of our study was to assess the diagnostic utility of basal LH for the diagnosis of central precocious puberty (CPP) in girls.
  • All subjects underwent GnRH-stimulation tests as part of their evaluation.
  • Serum LH and follicle stimulating hormone (FSH) were measured by immunoradiometric assay before and after the GnRH injection.
  • Basal LH level was identified as a significant predictor for CPP.
  • Based on the ROC curve, the optimal cut off point of basal LH related to 'pubertal response' was 1.1 IU/l, which was associated with 69.1% sensitivity and 50.5% specificity, with an area under the ROC curve of 0.620 (95% CI, 0.581-0.660).
  • It is concluded that a single basal LH measurement can be used as a screening test to identify girls with CPP and to determine who should undergo GnRH stimulation test.
  • [MeSH-major] Luteinizing Hormone / blood. Luteinizing Hormone / diagnostic use. Puberty, Precocious / blood. Puberty, Precocious / diagnosis
  • [MeSH-minor] Child. Cohort Studies. Female. Follicle Stimulating Hormone / blood. Gonadotropin-Releasing Hormone / blood. Humans. ROC Curve

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • HSDB. structure - MENOTROPINS.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 22893259.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


44. |||||||... 72%  Yang WC, Tang KQ, Li SJ, Chao LM, Yang LG: Polymorphisms of the bovine luteinizing hormone/choriogonadotropin receptor (LHCGR) gene and its association with superovulation traits. Mol Biol Rep; 2012 Mar;39(3):2481-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of the bovine luteinizing hormone/choriogonadotropin receptor (LHCGR) gene and its association with superovulation traits.
  • The objective of this study was to identify a predictor to forecast superovulation response on the basis of associations between superovulation performance and gene polymorphism, variation in the bovine luteinizing hormone/choriogonadotropin receptor (LHCGR) gene was investigated using PCR-single-strand conformational (PCR-SSCP) and DNA sequencing.
  • [MeSH-major] Genetic Markers / genetics. Polymorphism, Single-Stranded Conformational / genetics. Receptors, LH / genetics. Superovulation / genetics
  • [MeSH-minor] Animals. Base Sequence. Breeding / methods. Cattle. China. DNA Primers / genetics. Female. Follicle Stimulating Hormone / pharmacology. Genetic Association Studies / veterinary. Molecular Sequence Data. Polymerase Chain Reaction. Polymorphism, Single Nucleotide / genetics. Sequence Analysis, DNA / veterinary

  • HSDB. structure - MENOTROPINS.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21667104.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers; 0 / Receptors, LH; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


45. |||||||... 72%  Iwasa T, Matsuzaki T, Murakami M, Shimizu F, Kuwahara A, Yasui T, Irahara M: Reproducibility of luteinizing hormone hypersecretion in different phases of the menstrual cycle in polycystic ovary syndrome. J Obstet Gynaecol Res; 2009 Jun;35(3):514-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility of luteinizing hormone hypersecretion in different phases of the menstrual cycle in polycystic ovary syndrome.
  • AIM: We evaluated the reproducibility of an elevated luteinizing hormone (LH) level or elevated LH/follicle-stimulating hormone (FSH) ratio in different phases of the menstrual cycle in patients with polycystic ovary syndrome (PCOS).
  • Furthermore, we evaluated the influence of cycle days and body mass index on LH levels using different days from menses or withdrawal bleeding.
  • All patients with PCOS had elevated LH levels and LH/FSH ratio, polycystic ovarian morphology and chronic anovulation at diagnosis.
  • After their diagnoses, we measured serum LH and FSH in the early period and/or late period of the follicular phase.
  • RESULTS: The rate of patients with elevated LH levels and LH/FSH ratio were significantly higher in the late phase than in the early phase in PCOS.
  • In the early phase, only 52% of patients had elevated LH levels and LH/FSH ratio.
  • We failed to demonstrate an inverse relationship between the LH level and BMI.
  • CONCLUSIONS: LH levels of patients with PCOS were strongly influenced by the days from menses or withdrawal bleeding.
  • In the early period, the reproducibility of elevated LH levels or LH/FSH ratio was poor even in patients previously diagnosed with them.
  • [MeSH-major] Luteinizing Hormone / secretion. Menstrual Cycle / physiology. Polycystic Ovary Syndrome / secretion
  • [MeSH-minor] Adult. Body Mass Index. Female. Follicle Stimulating Hormone / blood. Humans

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • HSDB. structure - MENOTROPINS.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527392.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


46. |||||||... 72%  D'Amico AV, Braccioforte MH, Moran BJ, Chen MH: Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord; 2010 Jan-Mar;24(1):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.
  • PURPOSE: We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist.
  • [MeSH-major] Alzheimer Disease / mortality. Gonadotropin-Releasing Hormone / agonists. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Biological Markers / blood. Brachytherapy. Follow-Up Studies. Humans. Luteinizing Hormone / blood. Male. Middle Aged. Multivariate Analysis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Alzheimer Disease.
  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20556875.001).
  • [ISSN] 1546-4156
  • [Journal-full-title] Alzheimer disease and associated disorders
  • [ISO-abbreviation] Alzheimer Dis Assoc Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Markers; 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


47. |||||||... 72%  Llouquet JL, Crepin N, Lasne F: The problem of anti-doping control of luteinizing hormone in boxing. Drug Test Anal; 2013 Apr;5(4):277-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The problem of anti-doping control of luteinizing hormone in boxing.
  • Luteinizing hormone (LH) is physiologically produced by the anterior pituitary gland.
  • Male athletes may use pharmaceutical LH for doping since it increases the production of testosterone by testes.
  • This hormone is thus on the World Anti-Doping Agency (WADA) list of substances prohibited for males.
  • Anti-doping laboratories perform the assay of this hormone in urine and report abnormally elevated results.
  • Comparison of the descriptive statistics for 426 LH values observed in boxing and other sports showed significant differences.
  • An experimental study comparing urinary LH levels in 17 boxers before and after a match demonstrated a clear increase after the match.
  • The same observation was made for urinary follicle stimulating hormone (FSH) in all of the eight boxers tested for this other pituitary gonadotropin.
  • These observations have consequences for anti-doping controls, as the reference range for urinary LH levels must take into account the specificities of boxers.
  • Although to our knowledge such observations have never been described, other pituitary disorders have been reported.
  • [MeSH-major] Boxing. Luteinizing Hormone / urine
  • [MeSH-minor] Doping in Sports. Follicle Stimulating Hormone / urine. Humans. Male. Testosterone / urine

  • HSDB. structure - TESTOSTERONE.
  • HSDB. structure - MENOTROPINS.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 John Wiley & Sons, Ltd.
  • (PMID = 23315937.001).
  • [ISSN] 1942-7611
  • [Journal-full-title] Drug testing and analysis
  • [ISO-abbreviation] Drug Test Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


48. |||||||... 72%  Emons G, Sindermann H, Engel J, Schally AV, Gründker C: Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology; 2009;90(1):15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
  • The luteinizing hormone-releasing hormone (LHRH; also known as gonadotropin-releasing hormone) receptor can be utilized for targeted chemotherapy with cytotoxic LHRH analogues such as AN-152, in which doxorubicin is linked to [D-Lys(6)]LHRH.
  • In addition, apart from reproductive organs, which are normally removed during surgical therapy, other organs and hematopoietic stem cells do not express LHRH receptors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Doxorubicin / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Gonadotropin-Releasing Hormone / analogs & derivatives. Receptors, LHRH / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • HSDB. structure - DOXORUBICIN.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19521066.001).
  • [ISSN] 1423-0194
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GNRHR protein, human; 0 / Receptors, LHRH; 27844X2J29 / LHRH, lysine(6)-doxorubicin; 33515-09-2 / Gonadotropin-Releasing Hormone; 80168379AG / Doxorubicin
  •  go-up   go-down


49. |||||||... 72%  Cui J, Eldredge JB, Xu Y, Puett D: MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS One; 2011;6(7):e21730
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone.
  • With the major goal of assessing gonadotropin (luteinizing hormone, LH) contributions to LH receptor (LHR)-positive ovarian cancer cells, we have conducted a genome-wide transcriptomic analysis on human epithelial ovarian cancer cells to identify the microRNA-associated cellular response to LH-mediated activation of LHR.
  • METHODS: Human ovarian cancer cells (SKOV3) were chosen as negative control (LHR-) and stably transfected to express functional LHR (LHR+), followed by incubation with LH (0-20 h).
  • At different times of LH-mediated activation of LHR the cancer cells were analyzed by a high-density Ovarian Cancer Disease-Specific-Array (DSA, ALMAC™), which profiled ∼ 100,000 transcripts with ∼ 400 non-coding microRNAs.
  • FINDINGS: In total, 65 microRNAs were identified to exhibit differential expression in either LHR expressing SKOV3 cells or LH-treated cells, a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or amplification in cancer, such as miR-21, miR-101-1, miR-210 and miR-301a.
  • CONCLUSION: The overall impact on the transcriptome-level expression indicates that LH may regulate apoptosis and cell growth of LHR+ SKOV3 cells, particularly by reducing cancer cell proliferation, with some microRNAs involved in regulatory roles.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Luteinizing Hormone / pharmacology. MicroRNAs / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Gene Expression Profiling. Genes, Neoplasm / genetics. Genome, Human / genetics. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, LH / genetics. Receptors, LH / metabolism. Reproducibility of Results. Signal Transduction / drug effects. Signal Transduction / genetics

  • Genetics Home Reference. consumer health - LHCGR Gene.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • ResearchGate. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5340-4 [11034067.001]
  • [Cites] Lancet Oncol. 2011 Mar;12(3):273-85 [21345725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Obstet Gynecol. 2003 May;101(5 Pt 1):885-91 [12738145.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Genome Res. 2004 Oct;14(10A):1902-10 [15364901.001]
  • [Cites] Fertil Steril. 1997 Jun;67(6):1005-12 [9176436.001]
  • [Cites] Int J Biol Markers. 1998 Jul-Sep;13(3):165-8 [10079392.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1203-17 [16990141.001]
  • [Cites] Hum Reprod Update. 2007 Mar-Apr;13(2):143-62 [17071638.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] Endocr Rev. 2007 Jun;28(4):440-61 [17463396.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):227-40 [18182067.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9 [18458333.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6162-70 [18676839.001]
  • [Cites] Mol Cancer Res. 2008 Nov;6(11):1775-85 [19010824.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D98-104 [18927107.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D105-10 [18996891.001]
  • [Cites] Semin Reprod Med. 2009 Jan;27(1):43-51 [19197804.001]
  • [Cites] Fertil Steril. 2009 Apr;91(4):1152-8 [18371964.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):690-4 [10797292.001]
  • [Cites] PLoS One. 2009;4(4):e5311 [19390579.001]
  • [Cites] Nat Rev Genet. 2009 Oct;10(10):704-14 [19763153.001]
  • [Cites] Mol Cell. 2009 Sep 24;35(6):856-67 [19782034.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):893-8 [20164919.001]
  • [Cites] PLoS Comput Biol. 2010;6(7):e1000866 [20686687.001]
  • [Cites] Mol Cell Endocrinol. 2010 Nov 25;329(1-2):56-61 [20471448.001]
  • [Cites] J Cell Mol Med. 2010 Sep;14(9):2240-9 [20345848.001]
  • [Cites] Gynecol Oncol. 2010 Dec;119(3):543-8 [20869762.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • (PMID = 21765906.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK033973; United States / NIDDK NIH HHS / DK / DK069711; United States / NIGMS NIH HHS / GM / GM075331
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger; 0 / Receptors, LH; 9002-67-9 / Luteinizing Hormone
  • [Other-IDs] NLM/ PMC3134471
  •  go-up   go-down


50. |||||||... 72%  He Y, Zhang L, Song C: Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes. Int J Nanomedicine; 2010;5:697-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
  • A sterically stabilized, mitoxantrone-loaded liposome, tailored to target luteinizing hormone-releasing hormone (LHRH) receptor overexpressing cells, was developed to promote the efficiency of intracellular delivery of mitoxantrone through receptor-mediated endocytosis.
  • A protein assay of ligand coupling to the liposomal surface indicated that more than 60% of the LHRH peptides were inserted into the liposome bilayer.
  • In vitro cell culture studies revealed that the gonadorelin-modified liposomes bound to their target cells had significantly higher affinity and better antitumor efficiency than generic drug-loaded liposomes.
  • These events were presumed to occur through specific interactions of the LHRH with its cognate receptors on the cell surface.
  • It was concluded that the targeting properties of the delivery system would potentially improve the therapeutic benefits of mitoxantrone, as compared with nontargeted liposomes.
  • [MeSH-major] Drug Delivery Systems / methods. Gonadotropin-Releasing Hormone / analogs & derivatives. Liposomes / chemistry. Mitoxantrone / administration & dosage. Receptors, LHRH / metabolism
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Biological Transport, Active. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Cell Line, Tumor. Drug Carriers / chemistry. Female. Humans. Nanomedicine. Polyethylene Glycols / chemistry

  • HSDB. structure - NOVANTRONE.
  • ResearchGate. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):691-743 [10581328.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12962-7 [16123131.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):1063-9 [11029513.001]
  • [Cites] Front Neuroendocrinol. 2001 Oct;22(4):248-91 [11587553.001]
  • [Cites] Int J Oncol. 2002 Jan;20(1):181-7 [11743662.001]
  • [Cites] Pharm Res. 2002 Mar;19(3):265-9 [11934232.001]
  • [Cites] Cell Mol Biol Lett. 2002;7(3):889-94 [12378272.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):61-73 [12932638.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):149-55 [14659447.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Cell Mol Life Sci. 2004 May;61(9):1042-68 [15112052.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):37-41 [15128006.001]
  • [Cites] Biochim Biophys Acta. 1989 Dec 11;987(1):47-55 [2597686.001]
  • [Cites] Drugs. 1991 Mar;41(3):400-49 [1711446.001]
  • [Cites] Biol Reprod. 2005 Nov;73(5):851-9 [16033997.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):163-76 [16752077.001]
  • [Cites] Biol Pharm Bull. 2007 May;30(5):963-6 [17473443.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] Adv Exp Med Biol. 2008;614:285-96 [18290339.001]
  • [Cites] Arch Pharm Res. 2008 Apr;31(4):539-46 [18449514.001]
  • [Cites] Eur J Pharm Sci. 2008 Aug 7;34(4-5):333-44 [18573336.001]
  • [Cites] J Control Release. 2008 Sep 10;130(2):107-14 [18582982.001]
  • [Cites] Int J Pharm. 2008 Oct 1;362(1-2):60-6 [18598745.001]
  • [Cites] Eur J Pharm Biopharm. 2008 Oct;70(2):657-65 [18582570.001]
  • [Cites] Arzneimittelforschung. 2008;58(10):529-34 [19025064.001]
  • [Cites] Mol Pharm. 2009 Jan-Feb;6(1):246-54 [19049322.001]
  • [Cites] Mol Pharm. 2009 Jan-Feb;6(1):98-104 [19072653.001]
  • [Cites] Int J Pharm. 2009 Feb 23;368(1-2):24-30 [18973800.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1655-65 [19509261.001]
  • [Cites] Bioconjug Chem. 2009 Jun;20(6):1201-8 [19435362.001]
  • [Cites] Expert Opin Drug Deliv. 2010 Jan;7(1):79-96 [19947889.001]
  • [Cites] Biochim Biophys Acta. 1995 Jul 26;1237(2):99-108 [7632714.001]
  • [Cites] Cancer Lett. 1995 Nov 27;98(1):57-62 [8529206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7269-73 [8692981.001]
  • [Cites] Drugs Aging. 1996 Aug;9(2):122-47 [8820798.001]
  • [Cites] Drug Dev Ind Pharm. 2005 Jan;31(2):223-9 [15773289.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 1;70(1):161-9 [15919056.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4194-9 [10945629.001]
  • (PMID = 20957221.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 0 / Polyethylene Glycols; 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ PMC2948949
  • [Keywords] NOTNLM ; liposome / luteinizing hormone-releasing hormone receptor / mitoxantrone / tumor targeting
  •  go-up   go-down


top


2. Definitions


3. Related RMF webpages
1. luteinizing hormone
2. luteinizing hormone beta subunit
3. deficiency pituitary hormone anterior growth hormone
4. growth hormone releasing hormone hypersecretion
5. receptors pituitary hormone regulating hormone
6. hormones hormone substitutes and hormone antagonists
7. growth hormone releasing hormone
8. pituitary hormone deficiency anterior pituitary growth hormone
9. growth hormone
10. hormone antagonists
11. parathyroid hormone
12. adrenocorticotropic hormone
13. receptors pancreatic hormone
14. hypersecretion pituitary hormone
15. receptors gastrointestinal hormone
16. pituitary hormone c
17. receptors thyroid hormone
18. hormone replacement therapy
19. injection of other hormone
20. hormone c testicular
21. direct implantation hormone
22. deficiency pituitary hormone
23. antidiuretic hormone c
24. deficiency testicular hormone
25. hormone secretion pheochromocytoma
26. growth hormone hypersecretion
27. receptors parathyroid hormone
28. follicle stimulating hormone
29. corticotropin releasing hormone
30. intestinal hormone c
31. anti mullerian hormone
32. thyrotropin releasing hormone
33. neoplasms hormone dependent
34. human growth hormone
35. gonadotropin releasing hormone
36. receptors pituitary hormone
37. thyroid hormone resistance syndrome
38. thyroid stimulating hormone c
39. hormone c ovarian androgen
40. receptors corticotropin releasing hormone
41. adrenocorticotropic hormone acth deficiency
42. msh release inhibiting hormone
43. pituitary hormone releasing hormones
44. receptors thyrotropin releasing hormone
45. sex hormone binding globulin
46. follicle stimulating hormone human
47. parathyroid hormone related protein
48. thyroid hormone receptors alpha
49. thyroid hormone receptors beta
50. overproduction of growth hormone disorder

top


terms of use | advertising programs | contact us
© 2014 RecentMedicalFindings


Connect with the


RMF


audience;




Post your ad here!